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CHAPTER 1 INTRODUCTION & BACKGROUND
1.1 Basics of Radiotherapy
Radiation has been shown consistently capable of destroying cancer cells. For this
reason it is often used for the treatment of tumors. Most often this treatment involves the firing
of high energy photons (a particle of electromagnetic radiation) out of a linear accelerator (linac)
at the target region of interest. A sample linear accelerator is displayed in Fig. 1. The amount
of radiation delivered to a patient is defined as dose and measured in units of Gray (Gy).
Because radiation is dangerous to not only cancer cells, but also healthy tissue, the radiation
field is shaped to the target of interest to minimize the quantity of harmful radiation from
reaching healthy tissues. This shaping is done using primary collimators as well as multi-leaf
collimators (MLCs). Primary collimators, also called jaws, are large heavy metal blocks that
create a rectangular or square radiation field of a certain size. MLCs are tungsten leaves such
as those found in Fig. 2 which move back and forth to block unnecessary radiation from
reaching healthy tissues. MLCs can be used to create irregularly shaped fields that accurately
deliver dose to the tumor while minimizing dose to healthy tissue.
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Figure 1 An Elekta Infinity linear accelerator

Figure 2. A multi-leaf collimator (MLC) shapes the radiation field
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Two common methods (modalities) for radiotherapy are intensity modulated
radiotherapy (IMRT) and volumetric modulated arc radiotherapy (VMAT).

IMRT sub-

modalities include step-and-shoot and sliding-window. For step-and-shoot IMRT, radiation is
only turned on when the leaves are stationary. Leaves are moved into new orientations while
radiation is off. For sliding-window IMRT, leaves are allowed to move while radiation is turned
on. This allows for radiation to more precisely conform to the target. VMAT is similar to
IMRT except that the treatment head rotates around the patient and dose rate is adjustable during
delivery. This allows conformal target doses to be delivered in a relatively shorter period of
time. Depending on the treatment site and prescribed dose, VMAT may also reduce toxicity
probabilities.
Every patient’s tumor shape and anatomy are different. Thus, every patient requires an
individual treatment plan.

A treatment plan is defined by the mechanical orientation of the

MLCs and jaws as well as the amount of radiation being delivered (monitor units (MU)) and
the orientation of the treatment head (gantry angle). The treatment plan is comprised of a
sequence of control points containing each of these machines parameters. As the treatment is
delivered, the MLC/collimators moves, the gantry rotates, and MU is outputted according to
these control points.
1.2 Treatment Planning Optimization
Treatment planning optimization is an iterative process in which the aforementioned
machine parameters are determined so as to achieve a desired dose distribution that uniformly
covers the tumor with the prescribed dose while minimizing dose to healthy tissue. The
treatment planning system (TPS) used in this study was Pinnacle3 by Philips. The optimization
algorithm utilized herein as part of Pinnacle3 is a sequential quadratic programming (SQP)
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optimization algorithm from the NPSOL library.1 The dense SQP algorithm utilizes gradient
descent to achieve progressively more optimal treatment plans. 2,3 During each iteration, the
following steps are carried out: (1) a machine parameter is changed; (2) a 3D dose distribution
is calculated for the new plan; and (3) the quality of the new plan is assessed. For step 2, dose
is calculated using a dose calculation method. Two dose calculation methods are assessed as
part of this study and will be introduced shortly. For step three, plan quality is assessed using
a dose objective function. Put simply, a dose objective function is a series of dose-volume
objectives that the plan should ideally meet. These dose-volume objectives are best explained
in terms of dose-volume histograms (DVHs). Sample DVH curves are plotted in Fig. 3. Each
curve displays how much dose is delivered to each structure. Specifically, DVHs display what
percentage of each structure receives how much dose.

Figure 3 A sample dose-volume histogram (DVH) shows what percent volume of the regions of interest
(ROIs) receive what percentage of the prescription dose.

A volume greater than the tumor itself is treated. The tumor itself is labeled the gross
tumor volume (GTV). A margin of expansion is utilized to account for any nearby microscopic
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cancer involvement as well as any regional involvement (e.g. lymph nodes). This expanded
volume is labeled the clinical target volume (CTV). The internal target volume (ITV) is the
CTV expanded by a margin that accounts for any intra-treatment tumor motion due to patient
motion. Lastly, the planning target volume (PTV) is the ITV expanded by some margin to
account for any potential setup errors. The prescribed dose is delivered to the PTV to assure
that the CTV receives the prescribed dose.
1.3 Dose Calculation Methods
Dose calculation methods are responsible for accurately calculating the dose delivered
to the patient. The two main parts of a dose calculation method are the dose calculation
algorithm and the beam model. In general, there are three types of dose calculation algorithms:
(1) convolution-superposition, (2) Monte Carlo, and (3) Boltzmann Solvers.

Generally

speaking, convolution-superposition (CS)-based algorithms are fast but less accurate while
Monte Carlo (MC) and Boltzmann Solver-based algorithms are slower but more accurate. CSbased algorithms are most commonly used, however, as computers become increasingly faster,
Monte Carlo and Boltzmann Solver are also becoming increasingly common. Two calculation
algorithms were assessed as part of this study. First, Pinnacle3’s collapsed-cone convolutionsuperposition algorithm was assessed. This is the algorithm that our institution is currently
utilizing as part of treatment planning optimization. Second, ScientificRT’s SciMoCa Monte
Carlo algorithm was assessed. Unfortunately, Monte Carlo is still too slow to be routinely used
in treatment planning and optimization, therefore, SciMoCa is utilized to verify the accuracy of
CS dose calculation. Boltzmann Solver algorithms are introduced but are not an important part
of this study.
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Each brand of linac, each model of linac, and each individual linac is constructed
differently.

These differences mean that every linac must be modelled individually.

Furthermore, every commissioned linac energy must also have its own beam model. This
means every linear accelerator may have 2-3 beam models. Every treatment planning system
(TPS) utilizes a slightly different beam modelling process, but largely speaking these
parameters are consistent for each type of dose calculation algorithm. For instance, CS beam
modeling parameters include values of MLC and collimator transmission, minimum leaf
separation, effective source size, quantification of electron contamination, and many other
factors. In order to set these beam modelling parameters, a wide variety of dose measurements
are taken in a water tank. Beam modelling parameters are set so that the resultant calculated
doses match the measured doses as accurately as possible. It is important to understand that
dose calculation accuracy is not only dependent on the inherent dose calculation accuracy of an
algorithm (e.g. CS or MC), but also dependent on a high quality beam model which is able to
accurately calculate dose for a wide range of clinical cases. It follows that any differences in
dose between CS and MC may be due to inherent differences in the calculation algorithms or
may simply be due to poor beam modelling. Whereas the prior type of dose difference is
unavoidable, the latter dose difference is fully avoidable. When evaluating MC vs. CS dose
differences in this study, differences will be evaluated as avoidable or unavoidable. This step
is critical from the perspective of treatment planning QA.
1.3.1. Monte Carlo
Task Group report of the AAPM 105 serves as a great introduction to the basics of
Monte Carlo as well as current issues associated with the utilization of such algorithms. 4 Monte
Carlo is a statistical simulation method for calculating dose that relies on physical principles of
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radiation transport in matter. In Monte Carlo, a large (~108) number of particle histories are
simulated and recorded. For example, let a photon be generated and fired at the patient of
interest.

Using physical interaction probabilities, the distance to interaction as well as

interaction type can be determined. The particle is then transported to the interaction site and
the interaction simulated. These steps are repeated until all secondary particles leave the dose
grid or deposit all of their energy (E < pre-specified energy threshold). In Monte Carlo,
quantities of interest are recorded over a vast numbers of particle histories. The statistical
average of their cumulative effects is utilized to calculate the dose delivered to the patient.
The Monte Carlo algorithm utilized by this study was ScientificRT’s SciMoCa
algorithm. SciMoCa shares its fundamental concept with the voxel Monte Carlo (VMC) family
of codes, e.g. VMC++ or XVMC.5-7 SciMoCa is also based off a more recent series of papers
by Sikora et al.8-9 The beam model utilized is not clinically commissioned and is currently used
for research purposes only. For all calculations, unless otherwise stated, particle histories are
simulated to achieve 1% dosimetric variance at 70% max dose.
1.3.2. Convolution-Superposition
Convolution-superposition dose calculation was introduced by Thomas Mackie in
1984.11-13 The algorithm allows for the calculation of 3-dimensional (3D) dose in heterogeneous
patient anatomies for irregular field sizes. The basic process of CS is as follows. First, a Monte
Carlo kernel is calculated. This kernel, displayed in Fig. 4 represents how radiation will deposit
its energy in the patient or some medium relative to the interaction voxel (in bold). CS utilizes
two of these Monte Carlo kernels. The first is the primary kernel which accounts for dose
deposition for primary radiation – radiation originating from the target or source. The second
is the scatter kernel which accounts for dose deposited by secondary/scattered radiation –
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radiation originating from attenuated primary radiation. These kernels then undergo the process
of convolution superposition. The easiest way to think of convolution-superposition is as
follows. Every voxel in the patient or phantom is going to have some amount of primary and
secondary radiation interaction occur in it – this quantity is the photon fluence. However, the
dose from this interaction is not deposited entirely in the interaction voxel. Rather, the dose is
deposited in surrounding voxels in accordance with the kernels. By considering every voxel in
the patient as an interaction voxel, tracking the dose deposition to all other voxels using these
kernels, and summing all of these doses, a 3D dose distribution is acquired.

Figure 4 Monte Carlo calculated primary dose spread arrays. The numbers represent the dose deposited
in the voxel normalized to the collision KERMA in the interaction voxel.

There are several sub-types of convolution-superposition algorithms.

The CS

algorithm utilized herein was Pinnacle3’s collapsed-cone convolution-superposition algorithm.
Collapsed-cone was introduced in 1988 by Anders Ahnesjo as a means of reducing the
computational cost of standard convolution-superposition algorithms.14 One of the key
differences of collapsed-cone CS is that it utilizes an analytical Monte Carlo kernel calculated
using Eq. 1, where Aθ, aθ,, Bθ, and bθ are functions of the scattering angle θ and the beam energy
acquired from pre-calculated lookup tables. The first term accounts for primary dose while the
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second term accounts for secondary dose. It follows that dose can be calculated using Eq. 2
where D is the dose, f is a depth hardening correction factor, T is an approximate TERMA
distribution, ρ is the medium density, and h is the poly-energetic kernel. The variables r and s
correspond to the dose-deposition and interaction voxels respectively. The computational cost
of this integral is O(N6), where N is the number of voxels along one side of the dose grid.
However, by discretizing space into a spherical coordinate system, this computational cost can
be greatly deduced. Using a spherical coordinate system (l,m,n) comprised of conical shell
segments of solid angle Ωmn around Θm, φn, and of thickness Δr, dose can instead be calculated
using Eq. 3. Let η be a spatially varying function of the heterogeneous medium density. The
radiant primary energy along the line through all segments on the line is calculated via recursion
one voxel segment at a time as in Eq 4. Using this formalism, dose is instead calculated in
O(M∙N3) where M is the number of cones. This is a huge speedup and the key advantage over
collapsed-cone convolution-superposition over standard convolution-superposition algorithms.
𝒉𝒘 (𝒓, 𝜽) =

(𝑨𝜽 𝒆−𝒂𝜽 𝒓 + 𝑩𝜽 𝒆−𝒃𝜽𝒓 )

(1)

𝒓𝟐

𝒇(𝒓)

𝑫(𝒓) = 𝝆(𝒓) ∭ 𝑻(𝒔)𝝆(𝒔)𝒉(𝒔, 𝒓)𝒅𝟑 𝒔

𝑫 ( 𝒓) =

𝜼(𝒓) 𝟏
𝝆(𝒓) 𝒅𝟐𝒖

(2)

∑𝒎 ∑𝒏[𝒂𝒎 𝑹𝒑𝒎𝒏 (𝒓) + 𝒃𝒎 𝑹𝒔𝒎𝒏 (𝒓)]

(3)

𝑩

𝑹𝒔𝒎𝒏 (𝒓𝒊 ) = 𝑹𝒔𝒎𝒏 (𝒓𝒊−𝟏 )(𝟏 − 𝒃𝒎 𝜼𝒊 𝜟𝒓) + 𝑻𝒊 𝝆𝒊 𝜴𝒎𝒏 𝒅𝟐 𝒖 𝒃 𝒎 𝜟𝒓
𝒎

1.3.3 MC vs CS

(4)
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As stated recently, the primary difference between MC and CS is speed versus accuracy.
The loss of accuracy in CS (with respect to MC) is primarily seen in two circumstances. The
first inadequacy of CS is when the patient anatomy is particularly heterogeneous. Arnfield et
al. showed differences in Monte Carlo (PEREGRINE) vs. collapsed-cone convolutionsuperposition as large as 10% in a heterogeneous lung phantom for a 4x4 cm2 square field.15
The effects of heterogeneity on Monte Carlo and collapsed-cone calculated doses will be further
assessed as part of this study. The second inadequacy of CS is when the treatment plan is
comprised of many small segments. Zhao et al. showed collapsed-cone CS consistently overestimated PTV dose by 5% compared to MC. 16 Zhen et al. showed collapsed-cone was 3-4%
higher for IMRT and VMAT plans than Accuros XB’s (AXB) Boltzmann Solver algorithm. 17
For reference, AXB is typically considered similar in accuracy to Monte Carlo.18 For each of
these publications, collapsed-cone is shown to over-estimate target dose for complicated IMRT
and VMAT fields. The effect of beam complexity on this discrepancy will be analyzed as part
of this study.
Dose differences (MC vs. CS) due to heterogeneity are a result of inherent differences
in the calculation algorithms. CS is known to do a poor job of calculating dose in heterogeneous
patient anatomies.19 This is because the Monte Carlo kernels utilized by CS are calculated in a
homogeneous water phantom.

When heterogeneous (non-water) voxels are present, CS

accounts for patient heterogeneity using range scaling. In range scaling, the average mass
density of voxels between the interaction and dose-deposition voxels is calculated and utilized
when extracting values from the kernels. For single-scattered photons, dose deposition can
only occur exactly on the line between the interaction and dose deposition voxels. Therefore,
the range scaling approximation correction factor is perfectly accurate. However, for multiple-
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scattered photons, they will likely have interacted in voxels not directly between the interaction
and deposition voxels. As a result, the range scaling approximation factor will not be perfectly
correct. It is important to note that for multiple-scatter photons, the mean density of the entire
patient/phantom is utilized instead of the mean density between the interaction and deposition
voxels. This is done for two reasons. First, photons do not necessarily interact only in voxels
between the interaction and deposition voxels.
computational cost of the dose calculation.

Second, this approximation reduces the

In comparison, MC physically models the

interactions of particles (photons, electrons, positrons) in matter, thus allowing it to accurately
model the interaction of these particles in heterogeneous anatomies.
For CS and collapsed-cone CS algorithms, dose is calculated per control point, where a
control point is a planning parameter that defines the linac state (collimation positions, delivered
MU, gantry angle) at some point in the planned treatment delivery. For example, a VMAT
delivery might utilize a 4° control point spacing. This means that the collimator positions and
MU output are defined every 4°. Dose is calculated at each of these discrete gantry angles.
However, radiation is being outputted continuously along all gantry angles in the VMAT arc,
not at discrete angles. In comparison, MC simulates particle histories continuously at all
possible gantry angles. Thus, whereas the collapsed-cone algorithm investigated herein is
susceptible to dose differences due to gantry discretization, MC is not.
1.4 Treatment Planning QA
There exist many sources of dosimetric error and uncertainty.

It is the goal of

radiotherapy QA to ensure that dosimetric accuracy falls within some maximum permissible
level. If the difference between measured dose and expectation varies by more than this
maximum permissible level, or action tolerance, then some action should be taken to rectify the
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problem. The most commonly cited conclusion is that end-to-end dosimetric accuracy should
be within ±5%.20-22 However, ultimately what matters is not the delivered dose, but adequate
control of the tumor as well as acceptable values of normal tissue complication probability
(NTCP). Tumor control probability (TCP) is a formalism that defines the probability that the
tumor will be controlled given the prescription dose. The TCP-formalism utilized in this study
is the effective uniform dose (EUD)-based formalism developed by Niemierko et al. 23 It can be
calculated via Eq. 5 and Eq. 6 where EUD is the absorbed dose to the patient that when
homogeneously given to a tumor yields the same number of surviving clonogenic cells as the
actual heterogeneous dose distribution. In Eq. 5, vi is the partial fraction of the target volume
that receives dose Di. The parameter ‘a’ is a tissue-specific parameter that models how the
tumor or normal tissue of interest responds to inhomogeneous irradiation. TCP is subsequently
calculated from EUD where TCD50 is the homogeneous dose to the tumor that will result in a
50% control rate. γ50 is a tissue-specific model parameter that quantifies the slope of the doseresponse curve. The dose response slope determines the percent variation in tumor control
probability (TCP) per percent difference in target dose. NTCP quantifies that probability that
a dose of radiation to an organ at risk (OAR) will experience complications as a result of the
prescribed dose. NTCP can be calculated per Eq. 7 and Eq. 8. where TD 50(V) is the tolerance
dose that results in a 50% complication probability due to the partial, uniform irradiation of
volume V. The slope of the dose response curve is labeled m. Literature recommends that endto-end dose accuracy should be within 5%20-22, however, realistically, required dosimetric
accuracy will vary from case to case. This is because the required accuracy will vary with the
steepness/slope of the dose-response curve, γ50, as well as what is clinically achievable. For
instance, if γ50 is equal to 5.0, then TCP will drop by 5% per 1% decrease in target dose. If γ 50
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is equal to 1.0, then TCP will only drop by 1% for a 1% decrease in target dose. It follows that
a site with a low γ50 value will not require as stringent of dose accuracy, whereas a site with a
high γ50 value will require more stringent dose accuracy – perhaps 2 to 3%. However, this level
of accuracy is difficult to achieve. In the remainder of section 1.4, the limit of what is clinically
achievable is addressed within the scope of the following dosimetric uncertainties: machine
calibration, patient positioning accuracy, ROI segmentation and target deformation, tumor
motion, electron density calibration, and dose calculation. All-together, the processes by which
these dosimetric uncertainties are quantified and minimized is called treatment planning QA.
Treatment planning QA is broadly described in TG-53.24
𝑬𝑼𝑫 = (∑𝒊(𝒗𝒊 𝑫𝒂𝒊 ))𝟏/𝒂
𝟏

𝑻𝑪𝑷 =

𝐍𝐓𝐂𝐏

(6)
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𝒕
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The role of machine QA is to reduce systematic dosimetric uncertainties pertaining to
the linac to within an acceptable limit. Without properly managing daily, monthly, and yearly
machine QA, significant dosimetric uncertainties can find their way into clinical treatment.
Task Group reports 40 and 142 lay out recommendations for machine QA of linear
accelerators.25,26 For IMRT cases, output constancy of the machine must be within 3% daily
and 2% monthly. Lasers must be aligned within 1.5mm daily and 1.0mm monthly. In the
monthly QA check, the radiation-light field coincidence, optical distance indicator (ODI), jaw
positioning, and treatment couch positioning should all be within 1mm. The gantry read out
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must also be accurate within 1 degree of actuality. Electron and photon beam profile constancy
should be within 1% and electron beam energy constancy should be within 2%.
Correct patient positioning and immobilization ought to be assessed daily via image
guidance (e.g. cone beam CT (CBCT)) to reduce any potential dosimetric uncertainties.
Positioning uncertainty varies between treatment sites. For stereotactic brain radiotherapy
utilizing a head ring, expected uncertainty is 1mm.27 For breast and prostate radiotherapies
utilizing a Vac-Lok, positioning uncertainty is expected to be 6mm and 2mm respectively. 28,29
Rotondo et al. shows that H&N positioning errors are typically a few millimeters. 30 Kaur et al.
goes on to show that PTV dose volume constraints (D2/50/95/98) vary by about 1% for H&N cases
for setup errors of 1-2mm when using a 5mm PTV margin.31 Rudat et al. showed that TCP can
drop by 5% and 11% respectively for esophageal and prostate cancers as a result of clinically
relevant setup errors.32-33
The management of target motion has become increasingly important with the
introduction of image-guided radiotherapy. Intrafraction motions include respiratory, cardiac,
and gastro-intestinal. Tumor motion causes the CT to be distorted; the tumor and OARs are
blurred over the full range of their motions. Typically, the CTV is expanded by some margin
to account for the full range of motion of the target, however, inadequate margins can result in
under-dosing of the CTV. For lung tumor treatment, without the use of a more advanced
respiratory management technique, Machalakos et al. showed GTV D95, V95, and TCP all
changed by about 1.3 ± 3.8% due to intra-fractional breathing motion; a patient-specific 1-2cm
CTV-PTV margin was utilized.35 GTV dose difference for these metrics was as large as 10%
for 4% of the treatment cases. Given the significance of this dosimetric error, TG-91 addresses
the management of respiratory motions using more advanced techniques.35 There exist multiple
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more advanced methods for reducing the dosimetric uncertainties due to respiratory motion.
The most common of these methods are respiratory gating, breath-hold, and abdominal
compression. In respiratory gating, the tumor motion is tracked during the actual treatment.
Radiation is delivered when the tumor position is within a certain range. Using a phase-based
respiratory-gated 4D-CT technique, Lin et al. showed that dose differences to the PTV, bilateral
lungs, and OARs were minimal.36 For deep inspiration breath-hold (DIBH), the patient is
coached to inhale deeply and hold their breath so as to produce a reproducibly deep inhale
during pre-treatment CT and treatment. Using DIBH, Rosenzweig et al. showed PTV dose can
be increased from 69Gy to 88Gy with no increase in NTCP values.37 By compression the
patient’s abdomen, the patient’s breathing is forcefully minimized in order to reduce tumor
motion. This allows for reduced CTV-PTV margins and reduced NTCP rates. Sarkar et al.
shows lung NTCP rates can be reduced by 2% for both conformal and VMAT lung cancer
treatment plans.38 In general, the dosimetric effects of respiratory motion is small when
correctly accounted for using these techniques.
Accurate contouring of the GTV, CTV, and PTV volumes is necessary in order to
adequately account for microscopic cancer spread, patient motion, and setup uncertainty.
Accurate OAR contouring is necessary to accurately predict normal tissue complication
probabilities (NTCP). However, our ability to accurately delineate these structures suffers from
inadequate training of dosimetrists, human error, and a lack of consensus in regard to how the
planning volumes ought to be defined.39 In a study by Fiorino et al., inter-observer variability
in rectum contouring resulted in dose differences of 3-4% (standard deviation).40 In a SRS study
by Stanley et al., the median absolute difference in conformity index (CI) between reference
contours of the metastases and alternative contours drawn by 8 other physicians was 0.35.41
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Although DVH-based impacts were not assessed as part of this study, a mean absolute CI
difference of 0.35 is large. CI values can range from 0 to 1 (ideal coverage), so a difference of
0.35 is very significant.
The patient’s anatomy is subject to change over the course of radiation treatment relative
to the planning CT. However, dose is only calculated on the pre-treatment planning CT. Ideally,
a new CT would be taken every day, a new daily-plan generated, and a new daily-dose
calculated. However, given current constraints of the clinical workflow this is not feasible.
Instead, this new CT/plan/dose is only acquired when the change in the patient’s anatomy is
large enough to warrant pushing the patient’s treatment back a day. The dosimetric impact of
anatomical variation can be significant. For instance, van der Horst et al. showed that CTV D 98
coverage can drop by 10% due to inter-fractional tumor position variations. 42 In the case of
IMRT treatment of H&N cancer, Cheng et al. showed that reduction in the size of the target
volume over the course of treatment often resulted in increased dose the spinal cord, brain stem,
and parotid glands.43 For prostate cases treated using VMAT, Chow et al. showed that reduction
in the size of the patient over the course of treatment yielded approximately a 2-3% increase in
prostate and normal tissue dose per centimeter in reduction of the patient’s size (reduction
measured in terms of depth of the tumor).44 In order to mitigate these dose discrepancies, several
techniques have been developed. These include cone-beam CT (CBCT), deformable image
registration (DIR), and adaptive radiotherapy (ART). These processes are not covered as they
fall outside of the scope of this thesis.
CT images are 3D arrays of values which quantify the attenuability of radiation in matter
relative to water and air. This attenuability is quantified in Hounsfield Units (HU), also called
CT number. However, in dose calculation algorithms, calculation is based on the electron
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density of each voxel, not the HU. This is because the stopping power, or absorption rate, of
electrons is dependent on the electron density of matter. Thus, it is necessary to convert HU
into electron density (ED). This conversion is carried out using a CT-ED calibration curve.
Any inaccuracies in this curve can potentially introduce dosimetric error into the treatment plan.
Das et al. displays that CT-ED errors are more relevant for IMRT cases and for treatment sites
with pronounced high-density bone present.45 For IMRT cases, dosimetric differences due to
inaccurate CT parameters could be as high as 5% in the presence of bony anatomies.
Dose calculation accuracy is one of the greatest factors in the overall end-to-end
dosimetric accuracy of the radiotherapy workflow. Dose calculation accuracy depends partially
on the inherent accuracies of the dose calculation algorithm, but also upon the quality of the
measurement data that was used in the beam modeling as well as the accurate determination of
beam model parameters in the treatment planning system. Dose calculation accuracy in
heterogeneous media needs to be thoroughly established. The ability to accurately calculate
dose for complex treatment fields also needs to be thoroughly vetted. In section 1.3.3 the effects
of heterogeneity were shown to cause local calculation differences on the order of 10%. In the
same section, collapsed-cone IMRT and VMAT fields were shown to consistently overestimate dose by approximately 3% relative to Monte Carlo dose calculation.17
The linear accelerator needs to be able to accurately deliver the treatment plan precisely.
This includes accurate reproduction of field sizes, gantry angle, machine output, MLC
positioning, etc.

A study by Moran et al. tabulates the accuracies of various delivery

components as well as their corresponding dosimetric impacts.46 Collimator output factors are
typically accurate within 0.5-1.0%.47 MLC positioning accuracy is typically less than 1mm,
however the effect this error has on dose is highly dependent on the gap between adjacent
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leaves.48 For example, Nithiyanantham et al. shows dosimetric errors can be as high as 6% per
millimeter of MLC error for plans with steeper dose gradients. The gross effect of leaf
transmission errors can result in dose differences as high as 3% for poorer treatment models. 49
The table top must be accurately accounted for in the treatment planning system.

Not

accounting for the table top, or accounting for it incorrectly can result in local dose differences
as high as 10-15% at certain gantry angles.50
Although it is fairly easy to isolate each of these dosimetric uncertainties and quantify
them separately, it is more difficult to evaluate their combined effects. Furthermore, the effects
of these dosimetric uncertainties will vary case to case. So then how do we know if the
dosimetric accuracy of each patient’s plan is within the ±5% limit that is required? The best
way to verify your treatment planning QA is to plan, treat, and measure dose as delivered to an
anthropomorphic (heterogeneous anatomically-realistic) phantom. The radiological physics
center (RPC) at M.D. Anderson Cancer Center provides these anthropomorphic phantoms to
institutions for the credentialing of linear accelerators. After your institution has delivered a
radiation treatment plan to the phantom, RPC evaluates the dose that was delivered to implanted
TLD detectors to determine that your institution was able to properly deliver the specified
radiation dose to the target while sparing surrounding tissues. Molineu et al. analyzes the ability
of 763 institutions to accurately deliver IMRT dose to an anthropomorphic head and neck (H&N)
phantom.99 This data, acquired from 2001-2011, provides an idea of what is a clinically
achievable measure of dose accuracy. 31% of the institutions failed to deliver dose to the target
within ±5%. A more recent study by et al. looks at data for the same H&N phantom but between
November 2014 – October 2015.100 Results show that 77% of institutions were able to pass a
5%/4mm gamma criteria. 50% of failures were due to systematically low delivered dose.
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verifying

your

institution’s

end-to-end

dosimetric

accuracy

using

an

anthropomorphic phantom is ideal, such a phantom may not always be available.
Short of using an anthropomorphic phantom with implanted dosimeters, TG-119 is an
apt commissioning test for verifying accurate dose. TG-119 puts forth a variety of clinically
relevant test cases which institutions can use to assess the accuracy of IMRT delivered dose.49
It is the task of each institution’s physicists to create a treatment plan for each test case, irradiate
a solid water stack in accordance with said treatment plan, measure the resultant dose at two
pre-specified high dose and low dose points using an ion chamber, and calculate the percent
difference in calculated and measured doses. This commissioning test verifies that your
treatment planning QA was effective. Specifically, TG-119 verifies that your machine QA,
machine delivery, and dose calculation are correct/accurate.

Because this test lacks an

anthropomorphic phantom, these tests are incapable of verifying correct patient positioning,
accurate accounting for patient heterogeneity, and an accurate CT-ED table. This test also does
not assess the correct handling of inter- and intra-fraction target motion. TG-119 contains
results for 10 institutions. Dosimetric accuracy is reported as a confidence limit (the mean
calculation error (relative to measurement) plus 1.96 times the standard deviation).51 On
average, over all treatment sites and all institutions, confidence limits were 4.5% in high dose
regions and 4.7% in low dose regions. This data suggests that dosimetric differences greater
than 5% occur about 5% of the time. In comparison, RPC showed that dose difference was
greater than 5% about 20% of the time. This difference is attributed to the fact that TG-119
utilizes a homogeneous solid water phantom whereas the RPC results utilize an
anthropomorphic phantom. These results also agree with previous studies that a 5% dose
accuracy is achievable and should be the minimum accuracy an institution aims to meet. In
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conclusion, although TG-119 is not a true end-to-end test set, it is an easy way to evaluate the
combined dosimetric effects of several important treatment planning uncertainties.
1.5 Patient-Specific Quality Assurance
1.5.1 Phantom-based QA
Linear accelerators are complicated devices comprised of many moving parts. It follows
that there will be some non-zero delivery error when delivering a treatment plan. The purpose
of patient-specific QA is to verify that radiation is being correctly delivered for each specific
patient’s treatment plan. Patient-specific QA is conventionally carried out using phantombased systems. The phantom-based systems utilized herein are Sun Nuclear’s MapCHECK and
ArcCHECK systems, shown in Fig. 5 and Fig. 6. MapCHECK is a planar device that contains
a planar array of diodes. A diode is a small (0.019mm3) device for measuring dose.

The

ArcCHECK phantom is a cylinder made of nearly tissue-equivalent material. Inside of the
cylinder are 1386 diodes arranged helically throughout the cylinder. Whereas MapCHECK2 is
used to QA radiation fields without gantry rotation, the ArcCHECK is utilized for fields where
gantry rotation is present. These QAs are carried out as follows. First, dose is calculated on
the phantom geometry. Next, the treatment plan is physically delivered onto the phantom. Dose
is measured using the diodes and compared to that of calculation to make sure the treatment
plan can be accurately delivered by the linac. MapCHECK2 and ArcCHECK QAs both utilize
gamma analysis to determine whether the QA is deemed passing or failing. The equations
underlying gamma analysis, shown in Eq.9 and Eq. 10, were developed by Low et al.52 Gamma
analysis is based on the concepts of dose difference (DD) and distance-to-agreement (DTA),
where DD is simply the percent difference in dose between calculation and measurement at the
spot of the diode of interest and DTA is the minimum distance it takes from the diode of interest
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to reach a voxel in the calculated dose distribution with the case dose as the diode measurement.
Let r(rm,rc) and γ(rm,rc) be the DTA measurement and DD measurement percent between the
diode of interest rm and some voxel in the calculated dose distribution r c. Similarly, let Δd2m
and ΔD2 M be the DTA and DD criteria that we are looking to meet. Common gamma criteria
are 2%/2mm – 3%/3mm. A 3%/2mm gamma criteria is utilized by our institution. Eq. 9 solves
voxel-wise for Γ, a composite quantity evaluating the combined effects of DD and DTA in
voxels proximal to the diode of interest. The per-diode gamma index, γ, is simply the minimum
value of Γ surrounding the diode. If γ is less than 1, the measurement result of the diode is
considered passing. If γ is greater than 1, the result for that specific diode is considered failing.
The combined gamma passing rate tells us what percentage of the diodes are passing or failing.
95-100% is considered passing, 90-95% is passing but warrants investigation, and less than 90%
is considered failing. In the case of failure, the QA should be re-done. If the plan still fails QA,
the plan should be re-planned.
𝚪(𝐫𝐦, 𝐫𝐜) = √

𝒓𝟐(𝐫𝐦,𝐫𝐜)
𝚫𝒅𝟐𝒎

+

𝛅𝟐 (𝐫𝐦,𝐫𝐜)
𝚫𝑫𝟐𝑴

𝛄(𝒓𝒎 ) = 𝐦𝐢𝐧{𝚪(𝒓𝒎 , 𝒓𝒄 )}∀ (𝒓𝒄 )

(9)
(10)
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Figure 5. SunNuclear’s MapCHECK2 planar diode array.

Figure 6. Sun Nuclear’s cylindrical ArcCHECK phantom

MapCHECK2, ArcCHECK, and other phantom-based QA methods have been the
standard of care for years. However, these measurement-based systems have come under fire
in recent years.

Several studies have shown diodes to be inaccurate measurement devices.

Saini et al. shows that diodes typically under-respond on the order of 1-4% for lower
instantaneous dose rates (~25 cGy/min) as opposed to typical clinical dose rate (> 200
cGy/min).53 Letourneau et al. shows MapCHECK diodes under-respond by up to 2% at 50
MU/min compared to 600 MU/min.54 Diode energy dependence has been explored by several
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studies, albeit to a lesser extent. 55-57 Yin et al. shows that unshielded Scanditronix diodes at
15cm depth can over-respond by as much as 15% to lower energy patient-scattered radiation.
However, for out-of-field diodes where the radiation spectrum can be significantly softer, one
should expect an even greater relative over-response by the diodes. For example, Rickner et al.
theorizes that diodes will over-respond to 100keV and 500keV photons by a relative 70% and
30% respectively.58 Comparing ArcCHECK diode measurement in a solid water slab to an ion
chamber, the ArcCHECK diode was shown to over-respond to radiation by up to 1% 5cm out
of field.101 Czarnecki et al. showed field size calibration factors to vary by up to 2.0% between
1x1 cm2 and 10x10 cm2 field sizes.59 However, after applying field size correction factors,
Chaswal et al. shows diode dose error as a result of field size dependence to be within 0.4% for
5x5 cm2 to 20x20 cm2 fields.60 The accuracy of the ArcCHECK diodes is assessed as part of
this study.
Debate-style manuscripts by Siochi et al. and Smith et al. state that measurement-based
IMRT is both time-consuming and potentially inaccurate since the measurements are taken in
a phantom and not the patient’s anatomy. 61,62 Furthermore, the reliability of these systems is
worrisome; 20% of institutions fail RPC’s 7%/4mm gamma criteria despite presenting with
acceptable gamma pass rates.63 Multiple studies have shown IMRT QA passing rates to be
weakly correlated with DVH-based metrics.64-66 Given this concern, there has been a general
movement towards DVH-based QA metrics. However, when it comes to DVH-based metrics,
phantom-based systems tend to fall short. SunNuclear does offer an ArcCHECK-specific
software package, 3DVH, for reconstructing 3D dose on the patient geometry from
measurement, however, Tyagi et al. shows that log files are better able to reproduce delivered
dose on the patient anatomy than this 3DVH software package.67 As part of this study, log file
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QA on the patient anatomy is compared to AC QA on the ArcCHECK geometry. The clinical
relevancy of AC QA passing rates is assessed. Furthermore, the effectiveness of phantombased QA as an anatomical surrogate is assessed.
1.5.2 Log File QA
Log files are records of treatment deliveries stored after each delivery. These files
contain a recording of collimator (jaw and MLC), gantry positions, delivered dose rate,
collimator angle, and MU output as a function of time. The Elekta log file utilized records log
files samples at 25Hz (every 40ms). In addition, the log file contains error values for the
collimator positions, gantry position, and collimator angle. Using these log files, a treatment
plan is reconstructed based on machine parameters from the actual delivery and dose calculated.
The log file reconstructed dose is then compared to the clinically planned dose. Log file dose
can be calculated on either the phantom geometry or patient anatomy. In the scenario that log
file dose is calculated on the phantom geometry, log file dose is compared to the clinically
planned dose using gamma analysis. However, when calculated on the patient anatomy, log
file dose can be compared to the clinically planned dose using the same DVH-based metrics
that were used to optimize the initial treatment plan
Log file QA offers multiple significant advantages over conventional phantom-based
patient-specific QA systems. Whereas phantom-based systems are time consuming, LF QA is
a fully automatable software system. Utilizing phantom-based systems, per-fraction dose
cannot be tracked. For example, ArcCHECK is setup before treatment to verify correct plan
delivery but is not utilized during actual patient treatment. In comparison, LF QA can be carried
out during every actual treatment fraction. By tracking dose to the patient per-fraction, a more
accurate cumulative dose distribution to the patient can be determined. In the case of significant
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dosimetric discrepancy relative to the clinically planned dose, the treatment plan can be adapted.
In addition, phantom-based systems are largely incapable of root-cause analysis. Phantombased QA is either passing of failing. For example, if ArcCHECK QA fails, it does not say
why. In comparison, LF QA allows for a robust root cause analysis – e.g. was the source of
error due to MLC error, gantry error, unstable MU output, or some other issue. Whereas
phantom-based systems ignore patient-specific anatomical variation, LF QA is capable of
tracking heterogeneous anatomic dose. In addition, LF QA provides the potential for online
treatment tracking and/or real time treatment plan modification. By tracking the log file in realtime, dosimetric discrepancy could also be tracked in real time. If the discrepancy were
significant enough, the treatment could be halted. Alternatively, the treatment plan could be
adapted in real time to instantaneously account for delivery error. It is noted that the current
log file system which has been provided to us by Elekta can only be used retrospectively; the
log file is not acquired in real time.
Skepticism with regard to the reliability of measurement-based phantom-based QA has
led researchers to investigate software-based log file QA as an alternative patient-specific QA
method.68-74 Using Varian’s dynalog system, Stell et al. showed MU errors were greater for high
dose rate deliveries.72 Handsfield et al. showed log-file based QA utilizing a secondary Monte
Carlo dose calculation method is an effective and efficient means of TomoTherapy QA. 70
Kumar et al. shows that log files can carry out IMRT QA with the same accuracy as film. 75 Log
files are also a viable method of VMAT QA for both phantom and patient geometries. 67,76
Defoor et al. shows that log file gamma passing rates as calculated on the patient anatomy
matched clinical gamma pass rates as calculated on the Delta4 phantom within 1%.76 Tyagi et
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al. shows that log file dose as calculated on the patient anatomy consistently agreed with the
planned dose within 2%.67
The primary concern with the use of log files is that they rely upon a reliable relationship
between machine read-out and the actual delivery. For example, in a Varian machine, MLC
leaf motor counts are converted into leaf position and output to the log file. As a result, a
malfunctioning MLC motor, faulty t-nut (connects the motor to the MLC), or loss of encoder
counts may result in incorrect log file reported MLC positions. Agnew et al. illustrates this
exact problem - a loose t-nut resulted in incorrect log file MLC leaf positions. 77 However, for
the Elekta machines at our institution, MLC positional information is determined based upon
the optically measured position of reflectors on each leaf, thus eliminating the possibility of
these catastrophic errors assuming that the optical reflectors have been calibrated correctly. At
our institution, MLC calibration is carried out via monthly picket fence/phantom tests. These
tests nominally ensure collimation components are within 1mm of post-calibration baseline
positions, however they can be somewhat subjective and don’t always directly isolate individual
leaf position errors. In addition, calibration can degrade over time. For these reasons, it may
be useful to perform Integrity’s Calibration Workflows more often or to implement a more
objective QA testing. In addition, log files do not monitor variations in output and beam tuning.
Thus, these factors must be sufficiently monitor via machine QA.
A second concern is that LF QA requires an accurate dose calculation method. Dose
calculation errors will go unnoticed by LF QA. It follows that having a robust dose calculation
method (algorithm + beam model) is of the utmost importance. In general, dose calculation
methods have been thoroughly vetted. For instance, using collapsed-cone CS, Butson et al.
showed dose calculation can be accurate within 5% of delivered dose for an anthropomorphic
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lung phantom.78 However, this 5% includes more uncertainties than just dose calculation
accuracy. It follows that the accuracy of the CS calculation method is likely in the 2-4% range.
In a study by Haga et al., MC and CS calculated doses typically agreed within ±2-5% with ion
chamber measurement in both solid water and cork phantoms.79 Calculations consistently
agreed within 1.5% of each other in target regions. These studies show that a dose calculation
accuracy of 2-3% is achievable. However, it is the responsibility of each institution to validate
the accuracy of their beam model(s). For instance, when it comes to LF QA, it is essential that
the calculated leaf position precisely matches the actual leaf position to account for subtle
discrepancies in leaf position as recorded in the log file. For CS, this is adjusted via the rounded
leaf tip offset table in Pinnacle’s beam modelling system.80 For MC, SciMoCa utilizes a
parameter that offsets the leaves from their nominal position as determined using a picket fence
test. All MLC positioning systems (log file, Pinnacle, SciMoCa) are nominally accurate to
0.1mm. Given the importance of dose calculation accuracy, two dose calculation algorithms as
well as two forms of LF QA were assessed as part of this study. The two dose calculation
algorithms were Pinnacle’s adaptive collapsed-cone convolution-superposition (CS) algorithm
and a research version of ScientificRT’s SciMoCa Monte Carlo (MC) algorithm.
The two forms of LF QA analyzed as part of this study were CS-based LF QA (LF-CS
QA) and MC-based LF QA (LF-MC QA). In LF-CS QA, the log file reconstructed and planned
doses both utilize the same CS dose calculation algorithm. Because the doses utilized the same
dose calculation method, patient-specific dose calculation accuracy is unknown. However, for
LF-MC QA, the log file reconstructed dose instead uses Monte Carlo for dose calculation. Thus,
LF-MC QA not only assesses the ability of the machine to accurately deliver the treatment plan,
but also acts as a secondary dose verification system. All three terms, LF QA, LF-CS QA, and
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LF-MC QA will be used during this study. Where LF QA will be used when referring to log
file quality assurance as a whole, LF-CS QA and LF-MC QA are more specific terms signifying
that log file reconstructed dose is being calculated using either CS or MC respectively.
LF-MC QA also functions as a means of treatment planning QA. As part of treatment
planning QA, the dosimetric impact of various beam modelling parameters and machine
delivery parameters are analyzed. These include jaw positioning accuracy, MLC positioning
accuracy, and linear MU output. The log file monitors each of these factors. Furthermore, LF
QA can be used to calculate the dosimetric impact of these factors per-patient on their unique
anatomy. It may be the case that current machine QA tolerances for these factors are too lax
and need tightened, or perhaps the tolerances we have in place are not that necessary. Log files
may also present with MLC/gantry errors that are greater than the tolerances set by machine
QA. More specifically, machine QA requires MLC positioning to be within ±1% and gantry
positioning to be within 1°, however, the log file may contain errors greater than these values.
In this circumstance, the dosimetric impact of these errors ought to be investigated. If deemed
significant the cause of this error can then be investigated and potentially corrected for. As an
example, perhaps MLC errors greater than what are allowed are occurring when MLC velocities
are greater than some value. Or perhaps gantry errors greater than the 1° machine QA tolerance
are occurring when gantry accelerations exceed some value. MLC velocities and gantry
acceleration values could then be constrained inside of the treatment planning system so that
MLC and gantry errors are within tolerance. It is noted that the effect of MLC and gantry
rotation on MLC and gantry error are not included in routine machine QA. By utilizing LFMC QA, the effects of beam complexity and patient heterogeneity can also be investigated.
Previously it was shown that MC and CS can disagree by 3% for IMRT treatments, despite
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agreeing well for simpler conformal plans. 17 This suggests these calculation differences likely
result from imperfect CS and/or MC beam modeling and/or treatment planning parameters.
1.6. Chapter Overview
The primary purpose of this study was to compare LF QA to ArcCHECK QA (AC QA).
In this chapter, many of the primary advantages and disadvantages of the two systems were
investigated. Chapter 2 is the first of two core chapters in this dissertation. Herein, diode
sensitivity dependencies of AC QA diodes were quantified. In addition, LF QA was compared
to AC QA when all doses were calculated on the ArcCHECK phantom geometry. In Chapter
3, LF-CS QA and LF-MC QA was carried out on the patient’s anatomy, allowing for log file
reconstructed dose to be directly compared to the clinically planned anatomical dose. Because
LF-MC QA is not well established, a protocol for assessing log file reconstructed anatomical
dose differences was developed. Using this protocol, anatomically-calculated LF-MC QA
results were compared to clinical phantom-based AC QA results. Chapter 4, provides a brief
overview of the LF QA software that was developed as part of this project. This software
includes automation tools for both LF-CS and LF-MC QA. Finally, in Chapter 5, conclusions
and the key clinical takeaways of this study are discussed.
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CHAPTER 2 LF QA FOR TREATMENT PLANNING AND DELIVERY QA: PART 1
– ARCCHECK GEOMETRY
2.1 Introduction
This is largely a comparative study, seeking to determine whether log file QA can
provide ArcCHECK equivalent accuracy. First, accuracy of the log file is investigated and the
Monte Carlo beam model is validated. Next, the log file dose reconstruction process along with
strategies for reducing the computational cost of said process was detailed.

Third, the

dosimetric uncertainty of ArcCHECK QA was re-investigated. Variation in diode sensitivity
as a function of dose rate, energy, and field size were investigated. The effect of these
parameters on measurement and subsequently ArcCHECK QA results was evaluated.
Calculated vs. AC-measured dose differences were quantified as functions of diode dose rate
and energy dependence. LF and AC QAs were evaluated for experimental plans of varying
delivery complexity. Lastly, clinical LF QA and AC QA results were compared. In this Chapter,
log file doses are all reconstructed on the ArcCHECK geometry.
2.2. Methods and Materials
For this study, an Elekta Infinity linac equipped with the Agility beam-limiting device
was utilized. Plans were selected from previously treated patients that were planned and
optimized using the Pinnacle3 treatment planning system. Eleven dual-arc VMAT patients
were selected for this study (9 H&N, and 2 low dose rate brain). For the entirety of this thesis,
all fields were 6MV photon fields. The head and neck cases were selected for their high degree
of complexity and somewhat lower gamma pass rates. The two brain cases were selected to
compare how log file and ArcCHECK QAs respond to low dose rate deliveries. All 22 arcs
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were delivered to Sun Nuclear’s ArcCHECK phantom and log files recorded. All beams were
flattened, 6 MV.
To compare AC QA to LF QA, five dose distributions were determined for each plan:
Plan-CS, Plan-MC, LF-CS, LF-MC, and AC. ‘Plan’ denotes the dose distribution that was
calculated from the original clinical treatment plan file optimized in Pinnacle, whereas ‘LF’
doses were calculated from log files. CS and MC denote the two dose calculation methods.
‘AC’ denotes ArcCHECK measurement. To begin, Plan-CS is recalculated using Monte Carlo
to get Plan-MC. Next, each plan was delivered on the ArcCHECK phantom, measurement
taken, and log files recorded.

For LF-CS dose calculation, in-house code was used to

reconstruct the log file beams in Pinnacle with a reduced number of log file samples (see Section
2.2). For MC dose calculation, the DICOM toolkit (DCMTK) library by OFFIS was utilized
to convert log files into DICOM RTPLANs containing every log file sample with non-zero MU.
DCMTK is a collection of open-source C/C++/ANSI libraries and applications implementing
the DICOM standard. Whereas LF-MC is calculated using every useful log file sample, LFCS is calculated using a reduced number of log file samples.
2.2.1 Preliminary Validations
First, the accuracy of our MLC calibration was assessed. The accuracy of the log file
records is based on this calibration and thus is of the utmost importance. Elekta’s Log File
Convertor for Integrity R3.2 records linac delivery parameters (dose rate, gantry/collimator
angle, leaf/collimator positions, MU) every 40ms. MU readings are determined via an ion
chamber in the treatment head of the linac. Jaw positions are determined electronically via two
redundant potentiometer voltages.

MLC positions are determined from the video image

positions of optical reflectors on each MLC leaf. The accuracy of jaw and leaf positioning, as
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represented in the log file, hinges on machine calibration and QA. Jaw and MLC calibration is
carried out annually as well as after any relevant field service. Calibration is performed using
the internal Calibration Workflows contained in the Integrity R3.2 treatment control system
(TCS), specifically the optical, diaphragm, and leaf workflows. For monthly QA, picket fence
patterns are acquired with the iViewGT EPID and a BB array phantom aligned to the crosshairs
and compared to baseline images acquired just after Calibration Workflows to verify that leaves
and jaws are within 1mm of their baseline positions. If any of the collimation components
appear to be out of tolerance, the appropriate Calibration Workflow is re-run and the appropriate
picket fence test repeated.
The ArcCHECK phantom was supported by the iBeam evo H&N extension. To account
for this added attenuation, a couch ROI was added to the phantom geometry in Pinnacle beneath
the ArcCHECK. In order to create this couch ROI the following process was carried out. A
solid water stack was set on top of the H&N extension and a standard farmer chamber was
inserted into the solid water stack at 10cm depth. Seventeen 10x10 cm2 fields were delivered
to the solid water stack at 17 different gantry angles. These angles were 100° to 260° with 10°
spacing between them. Measurement was compared to calculation with this added couch ROI.
The ROI was optimized to maximum agreement between CS dose calculation and measurement
for the greatest number of these 17 fields.
As discussed in Chapter 1, the accuracy of CS and MC is generally well established,
however, beam modeling accuracy is linac specific and must be thoroughly validated by each
institution. Thus, both CS and MC beam models were first thoroughly validated by comparing
calculated dose to measurement data. Measurement data for the 6MV Elekta Agility linac was
acquired using IBA’s Blue Phantom2. Inline/crossline profiles, PDDs, and output factors were
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acquired for a variety of field sizes ranging from 1x1 cm2 to 40x40 cm2. These field sizes are
displayed in Table 3 in the results section. Output factors and PDDs and percent depth dose
data for field sizes less than 5x5cm2 were acquired using a Sun Nuclear EDGE diode. All other
measurements were acquired using an IBA CC13 ion chamber (0.13 cm3 volume, 5.8 mm
length, 3.0 mm radius). Crossplane profiles were offset half a leaf width (2.5 mm) in the inplane
direction to minimize the effect of interleaf leakage and to scan close to the center of the Agility
leaf tips which appear tapered in EPID images. All profiles were measured at 1.5/5/10/20 cm
depths. Ideally, large field profiles should be acquired using a microdiamond or microchamber.
For the ≥20x20cm profiles taken with a CC13 chamber, substantial penumbral blurring and
thus poorer agreement between measurement and calculation is expected. The resulting beam
model was validated by comparing calculated doses to each of the aforementioned
measurements.

All calculations utilized 1mm dose grid resolution in the direction of

measurement. In regard to commissioning and QA of treatment planning dose calculation,
Smilowitz et al. recommends low-gradient in-field regions match within 1.5%, penumbra agree
within 3mm DTA, and out-of-field measurements agree within 3% of max dose. 81 Therefore,
the fraction of calculations that meet each of these criteria was determined. Out-of-field doses
were also compared using more strict 2% and 1% criteria. Low-gradient was defined as less
than 1cGy/mm. Out-of-field was defined as less than 10% of CAX dose. Additional per-field
calculations included percent difference in output factor, mean percent difference in PDD from
0-35cm, mean percent difference in beam width (50%-50%) over all eight profiles, and mean
percent difference in penumbral width (80%-20%) over all eight profiles. Percent PDD
differences were calculated relative to maximum dose. Due to insufficient scan length for the
40x40 field, out-of-field dose and penumbral width was left uncalculated and unanalyzed.
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2.2.2 Strategies for Reducing the Computational Cost of LF-CS QA
Log files are reconstructed by converting n number of log file samples into n VMAT
control points, where a control point is a planning parameter that defines the linac state
(collimation positions, delivered MU, gantry angle) at some point in the planned treatment
delivery. However, Pinnacle places an upper limit of 359 control points on each field, thus
limiting the number of log file samples that can be reconstructed to 359, despite thousands of
samples per log file. In addition to this software limit, utilizing every one of thousands of log
file samples would result in extremely long CS calculation times. This is because CS dose
calculation time scales linearly with the number of control points for the CS method. There are
at least a few ways to reduce this cost: (1) utilize CPU and/or GPU parallelization, (2) utilize a
dose calculation algorithm whose computational cost is independent of the number of control
points (e.g. Monte Carlo), and/or (3) reduce the number of log file samples reconstructed. For
this study, methods 2 and 3 were investigated. CS dose calculation utilized Oracle’s Sun Server
X4-2. MC calculation utilized an Intel i7-3770 and 8GB of RAM.
The effect of reducing the number of log file samples reconstructed was investigated by
utilizing 1/2/3/4º control point spacing. For example, a VMAT arc starting at -179º, ending at
179º, and reconstructed with a 3º control point spacing would have the following control points:
-179.xº, -176º, -173º, … 175º, 178º, 179.xº. Variable x stands for the exact gantry angle at
which radiation started and stopped delivering radiation according to the log file. In addition
to control point spacing, the effect of dose grid resolution (2/3/4 mm) on log file reconstructed
dose accuracy was analyzed. Reconstructive effectiveness was quantified by comparing log
file gamma pass rates (LF-CS vs. AC) with pass rates of the original plan (Plan-CS vs. AC).
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This metric measures dosimetric improvement due to log files accounting for machine delivery
errors. Because LF and AC both account for delivery errors, this metric should be ≥ 0.
2.2.3 Discrepancy in Calculated vs. Measured Diode Doses
The ArcCHECK phantom contains 1386 diodes whose job is to measure the dose
delivered to the phantom. However, this measurement can be inaccurate due to various diode
sensitivity dependencies. Diode sensitivity dependence is evaluated as a function of dose rate,
energy, field size, and field complexity. By quantifying these dependencies the accuracy
ArcCHECK dose measurement can be better understood.
2.2.3.1 In-Field Discrepancy: Dose Rate Effect
Calculated (Plan-CS) vs. measured (MapCHECK2 and ArcCHECK) doses were
compared for a variety of dose rates (35, 70, 140, 280, and 570 MU/min). 150MU was delivered
onto the MapCHECK2 diode array for 3x3cm2 and 20x20cm2 field sizes and each dose rate.
Constant machine output was verified by placing 2cm solid water on top of the MapCHECK
and inserting an ion chamber at CAX.

In-field and out-of-field dose rate effects were

investigated; penumbral diodes directly on the field edge were excluded from the analysis.
MapCHECK2 was initially utilized in order to best isolate dose rate effects; the simpler device
geometry minimizes any possible spectral effects. It is important to note that the same diodes
are used in both MapCHECK2 and ArcCHECK systems. Systematic effects of dose rate on
AC QA and LF QA were assessed by delivering a 25x25arc onto the phantom using 70 and 570
MU/min.
Dose rate is dynamically determined based upon gantry, jaw, and leaf speed limitations.
Thus, for deliveries with fixed jaws and leaves, delivered dose rate should be calculable as a
function of MU, gantry excursion (gantry degrees subtended), and maximum gantry speed
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(6°/s). To prove this, 23 10x10 arcs (see Table 1) with varying gantry excursions and MU were
delivered on the ArcCHECK phantom. ‘Calculated’ dose rate matched log file data for all cases.
Next, percent difference in calculated (Plan-CS) and measured diode dose was tracked for each
of the 23 fields and analyzed as a function of ‘calculated’ dose rate.
Table 1. 10x10 arcs of varying gantry excursions and MU

Gantry Start/Stop/Excursion
-90 / -60 / 30
-90 / -30 / 60
-90 / 30 / 120
-90 / 90 / 180

MU
10, 20, 35, 50, 100
20, 40, 70, 100, 200
20, 40, 80, 140, 200, 400
20, 40, 60, 120, 210, 300, 600

2.2.3.2 Out-of-Field Discrepancy: Energy Effect
Percent difference in calculated versus measured diode dose was analyzed as a function
of off-axis distance to determine the effects of off-axis softening on AC QA. Because off-axis
spectra vary with field size, static 2x2 cm2, 10x10 cm2 and 25x25 cm2 arcs were assessed. 0%
and 10% dose thresholds were utilized.
2.2.3.3. Delivery Complexity
The effect of beam segment complexity on calculated vs. measured dose difference was
investigated for 42 fields delivered onto the ArcCHECK phantom. 100MU static fields were
delivered at gantry 0° and -90° for 1x7 cm2, 7x1 cm2, 2x8 cm2, 8x2 cm2, 3x5 cm2, 5x3 cm2, 5x1
0 cm2, 10x5 cm2, 2x2 cm2, 3x3 cm2, 5x5 cm2, 10x10 cm2, 15x15 cm2, and 20x20 cm2 field sizes.
300MU arcs from -90° to 90° were delivered for the same field sizes. Two metrics, MPDD
(mean percent dose difference) and MAPDD (mean absolute percent dose difference), were
utilized. These metrics work by comparing any two of the five dose distributions described in
Section 2.2 at each of 1386 ArcCHECK diode positions. Equation 1 shows how to calculate
MAPDD for LF-MC vs. AC where i is the i-th diode (i = 1-1386) such that ACi is greater than
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some threshold percentage of max(AC). MPDD is simply MAPDD without taking the absolute
value.
𝑳𝑭𝑴𝑪𝒊 −𝑨𝑪𝒊

𝑴𝑨𝑷𝑫𝑫 = 𝑴𝒆𝒂𝒏 (|

𝑨𝑪𝒊

∗ 𝟏𝟎𝟎|)

(11)

LF QA and AC QA should agree with one another even for complex fields. To verify
this is the case, we divided a 12x12 cm2 static field and 12x12 cm2 arc into 1/4/9/16/36 subfields (i.e. 1 12x12 cm2, 4 6x6 cm2, 9 4x4 cm2, 16 3x3 cm2, and 36 2x2 cm2 fields/arcs). Each
static field was setup at gantry 0. Arcs were a full 358° CW or CCW. Plans were generated in
Pinnacle on a ‘prescription’ geometry and then re-calculated and delivered on the ArcCHECK
geometry. The prescription geometry, shown in Fig. 7, consisted of three structures. A
20x20x20 solid water cube centered on the isocenter serves as the patient volume. A 10x10x10
‘Target’ ROI centered on isocenter was utilized for DVH matching purposes; all static fields
and arcs had matching DVHs. Lastly, an isocenter-centered 10x10x1 (1cm perpendicular to
gantry 0° CAX) ‘Prescription’ ROI was created. Sub-field beam weights were optimized to
achieve a flat beam profile at 10cm depth for the full field; dose was optimized to the
Prescription ROI using a 1Gy minimum DVH objective and 1.1Gy maximum DVH objective
of equal priority. Static field beam weights were copied to their corresponding arc fields. Each
set of sub-fields was delivered onto the ArcCHECK phantom. Sub-field measurements were
combined such that ten combined-field measurements (5 static field and 5 arc) were created.
Differences in AC, Plan-CS, Plan-MC, and LF-MC doses were assessed as a function of the
size and number of segments delivered.

38

Figure 7. (left) The ‘prescription’ geometry. The teal isodose line displays the flatness of the combined
12x12 field when (right) 36 abutting 2x2 fields are delivered

2.2.4 Comparing LF QA & AC QA
Plan, LF, and AC dose distributions are subject to varying sources of dose uncertainty
and share various correlated factors. AC QA compares ‘Plan’ and AC doses; discrepancies
stem from phantom-dependent inaccuracies (e.g. setup error, diode miscalibration/drift, diode
sensitivity dependencies, and physical diode limitations), dose calculation inaccuracy, delivery
error, and variation in beam consistency (drift in beam output/symmetry). LF and AC doses
both account for delivery error. It follows that LF and AC doses should agree better than Plan
and AC doses. For LF QA, LF and Plan doses are compared. Conventionally this means
comparing LF-CS to Plan-CS to isolate delivery error. However, dose calculation accuracy
should also be verified. By comparing LF-MC to Plan-CS, both delivery error and dose
calculation accuracy are investigated. It is important to note that whereas AC accounts for
variations in beam consistency, neither LF nor Plan doses do. This means that LF QA ignores
variation in beam output.
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AC and LF QAs were carried out for 11 clinical dual-arc VMAT patients (9 H&N, 2
low dose rate brain). Dose was determined at each of ArcCHECK’s 1386 diode locations for
each arc and each of the five aforementioned dose distributions. Various pairs of these five
plans were compared. Plan pair comparisons included (1) Plan-CS vs. AC, (2) Plan-MC vs.
AC, (3) LF-CS vs. AC, (4) LF-MC vs. AC, (5) Plan-MC vs. Plan-CS, (6) LF-CS vs. Plan-CS,
(7) LF-MC vs. Plan-MC, and (8) LF-MC vs. Plan-CS. Three comparisons metrics were utilized.
First, 2%/2mm and 1%/1mm global gamma pass rates were calculated using 10% (conventional)
and 85% (in-field/target approximation) dose thresholds.

Second, global percent dose

difference was calculated at each diode position and averaged over all diodes (1386 diodes/arcs
* 22 arcs). ‘Global’ indicates that percent differences have been scaled relative to the maximum
dose value being compared to, e.g. for X vs. Y where X and Y are two 1386 element dose
matrices. Global percent diode dose difference (GPDDD) is calculated according to Eq. 12.
This second metric was calculated in order to isolate and quantify systematic and statistical
dose uncertainties due to delivery error, dose calculation difference, and the ArcCHECK
phantom (e.g. diode sensitivity dependencies) as well as to confirm the gamma analysis results.
The dosimetric comparisons studies as well as their significances are displayed in Table 2.
𝑿−𝒀

𝑮𝑷𝑫𝑫𝑫 = 𝒎𝒆𝒂𝒏 (𝐦𝐚𝐱(𝒀) ∗ 𝟏𝟎𝟎)
Table 2. Dosimetric comparisons along with their significance. When two comparisons are listed it is
because those two comparisons are being compared.

#
1

Comparison 1
Plan-CS vs. AC

2

Plan-MC vs. Plan-CS

3
4
5
6

LF-CS vs. AC
LF-MC vs. AC
LF-MC vs. Plan-MC
LF-CS vs. Plan-CS

Comparison 2
Plan-MC vs. AC
-Plan-CS vs. AC
Plan-MC vs. AC
---

Significance
Which dose calculation method
matches AC better?
Dose difference due to calculation
method is isolated.
Log files should match AC better.
Is this the case?
Machine delivery error is isolated.

(12)
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7

LF-MC vs. Plan-CS

Plan-CS vs. AC
Plan-MC vs. AC

How do LF QA and AC QA
compare?

2.3 Results and Discussion
2.3.1 Preliminary Validations
For the Elekta Infinity/Agility linac used in this study, Calibration Workflows
resulted in leaf, leaf bank, and jaw positions agreeing with nominal positions within
approximately 0.3mm each (0.1mm RMS). Despite the initial accuracy of these calibration
processes, agreement with nominal positions can degrade over time.

Monthly picket

fence/phantom tests nominally ensure collimation components are within 1mm of postcalibration baseline positions, however they can be somewhat subjective and don’t always
directly isolate individual leaf position errors. For these reasons, it may be useful to perform
Calibration Workflows more often if utilizing LF QA clinically, or to implement more objective
collimator component QA testing.

The necessary increased frequency of calibration or

exploration of other QA methods were not investigated as part of this study.
The ArcCHECK phantom is supported by a H&N extension. A couch ROI was added
to the phantom geometry in Pinnacle to account for this added attenuation. Calculation was
compare to measurement for 17 10x10 cm2 fields delivered at 17 different gantry angles passing
through the H&N extension. With the added H&N ROI calculation agreed with measurement
within 0.25% for all seventeen fields. On average, calculation agreed with measurement within
0.10% for these fields.
Verification data comparing MC calculation to measurement is shown in Table 3. The
SciMoCa model utilized herein met each of the aforementioned AAPM recommended criteria
100% of the time. Furthermore, 96.5% of out-of-field measurement data matched calculation
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within 2%. For field sizes ≤ 20x20 cm2, 97% of out-of-field measurement data matched
calculation with 1%. For the larger 30x30 cm2 field size, 44% of measurement data matched
within 1%.

On average, over all field sizes, calculated output factors deviated from

measurement by 0.20 ± 0.17% and PDDs agreed within 0.65±0.19%. On average, beam width
varied by 0.54 ± 0.38%. On average, over all field sizes, and all profiles (both in-plane and
cross-plane at each depth), penumbral width varied by 1.1 ± 0.5% of the field size. The absolute
differences in penumbral width are shown per-field in Table 3. These values are shown in
parentheses. For field sizes less than or equal to 10x10cm this difference was within 0.5mm,
however penumbral width varied by almost 3mm for the 30x30 cm2 field; these absolute
differences are displayed in parentheses in Table 3.

As hypothesized, deviation in penumbral

width was larger for the profiles taken with the CC13 chamber (20x20 cm2 and 30x30 cm2)
than the EDGE diode (< 20x20 cm2). This larger deviation is expected to result from penumbral
blurring and not poor beam modeling.
Table 3. 6MV Elekta Agility Monte Carlo beam model validation results are shown. Absolute percent
differences in output factor (OF), percent depth dose (PDD), penumbral width (PW), and beam width
(BW) are shown for each field size. Due to insufficient measured profile length, differences in 40x40cm
penumbra were not calculated.
Field (cm)
OF |%Diff|
PDD Mean(|%diff|)
PW Mean(|%diff|)
BW Mean(|%diff|)
1x1
2x2
3x3
4x4
5x5
6x6
8x8
10x10
12x12
15x15
20x20
25x25
30x30
35x35

0.3%
0.4%
0.5%
0.0%
0.3%
0.4%
0.3%
0.0%
0.3%
0.1%
0.0%
0.2%
0.1%
0.1%

-0.64 ± 0.23%
0.95 ± 0.20%
-0.22 ± 0.12%
--0.51 ± 0.11%
-0.61 ± 0.11%
0.75 ± 0.10%
0.75 ± 0.12%
0.72 ± 0.17%
0.73 ± 0.17%

-1.9 ± 1.0% (0.4mm)
1.5 ± 1.1% (0.4mm)
-1.0 ± 0.3% (0.50mm)
--0.5 ± 0.3% (0.50 mm)
--0.7 ± 0.4% (1.5 mm)
-1.0 ± 0.3% (2.9mm)
--

-0.9 ± 0.5% (0.2mm)
1.0 ± 0.5% (0.3mm)
-0.8 ± 0.5% (0.4mm)
--0.6 ± 0.3% (0.6mm)
--0.1 ± 0.1% (0.2mm)
-0.14 ± 0.11% (0.4mm)
--
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40x40
All

0.0%
0.20 ± 0.17%

0.64 ± 0.25%
0.65 ± 0.19%

-1.1 ± 0.5%

0.25 ± 0.11% (1.0mm)
0.54 ± 0.38%

Combined:

2.3.2 Strategies for Reducing the Computational Cost of LF-CS QA
Fig. 8 displays change in pass rate ((LF-CS vs. AC) minus (Plan-CS vs. AC)) as a
function of control point spacing and dose grid resolution for 10 (8 H&N, 2 Brain) of the 22
clinical VMAT arcs used in this study. To make the plot clearer, error bars were plotted only
in one direction for each curve. For the dose grid resolution curve, 2° control point spacing is
utilized. 2mm resolution offers a 1.2±0.5% increase in pass rate compared to 3mm. For all
subsequent studies, a 2mm dose grid resolution was utilized. Increased control point spacing
resulted in lower LF-CS pass rates. Yielding a negative change in pass rate, control point
spacing ≥ 2° was deemed unacceptable. 1° LF-CS spacing was used throughout the rest of this
study. Similarly, Barbeiro et al. found log files reconstructed with ~3 times as many control
points as the TPS agreed better with film than those reconstructed with the TPS’
discretization.82
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Figure 8. Difference in 2%/2mm pass rate ((LF-CS vs. AC) minus (Plan-CS vs. AC)) is plotted as a function
of varying dose grid resolution (fixed 2° control point spacing) and control point spacing (fixed 2mm dose
grid resolution). For visualization purposes, error bars (1σ) are plotted only in one direction.

Computational cost for CS was typically 12 seconds per control point. This corresponds
to 18 minutes for a 358° arc planned with 4° control point spacing or 72 minutes for a log file
plan reconstructed using 1° control point spacing. In comparison, MC dose calculation took ~5
minutes to calculate log file dose using every control point. This discrepancy in computational
cost stems primarily from CS’s computational cost being dependent on the number of control
points, but also from the aforementioned differences in hardware.
2.3.3 Discrepancy in Calculated vs. Measured Diode Dose
2.3.3.1 In-Field Discrepancy: Dose Rate Effect
Fig. 9 plots in-field reduction in diode measurement with decreasing dose rate with
respect to 570 MU/min for 3x3cm and 20x20cm MapCHECK2 fields, a 25x25cm ArcCHECK
field, and the 23 10x10cm ArcCHECK fields in Table 1. For the MapCHECK2 measurements,
low dose rate (35 MU/min) measurements were -1.2±0.4% and -1.6±0.4% lower than the high

44

dose rate (570 MU/min) measurements for 3x3cm and 20x20cm fields respectively. The trend
shown in Fig. 9 is similar to Letourneau et al’s, although slightly less in magnitude; Letourneau
measured an under-response of -2.0% at 50MU/min.54 Variance in dose rate effect with field
size is believed to result from the reduced signal observed with smaller field sizes. Jursinic’s
‘hypothesized reaction scheme’ would suggest smaller signals are less susceptible to the dose
rate effect.83 Eq. 13 quantifies the ratio of diode sensitivity when traps are open to that when
traps are closed. The terms τd, τRG1, and τtrap1 are the charge lifetimes for the detection circuit,
recombination-generation (R-G) centers, and traps respectively. Charge lifetime is the average
time it takes for charge to enter and exit a system. Traps are locations in a solid that restricts
the movement of charge. These traps results as a function of chemical impurities or irregular
atomic spacings. R-G centers result from atomic impurities in semiconductors that introduce
additional allowed electron levels in the band gap, slowing charge collection in the
semiconductor diode. This would also explain why out-of-field diodes registered identical
doses for low and high dose rates. Delivering a static 25x25cm arc so that all diodes were infield, ArcCHECK measurement behaved similarly to MapCHECK2; measurement decreased
with decreasing dose rate. Lastly, delivered dose rate was calculated from MU and gantry
excursion for the 23 10x10cm arcs shown in Table 1. This ‘calculated’ dose rate matched the
actual log file determined dose rate for all cases. Subsequently, as displayed by the solid line
in Fig. 9, variation in in-field diode measurement as a function of dose rate agreed well with
previous results.
𝑺𝒕𝒓𝒂𝒑𝒔 𝒐𝒑𝒆𝒏
𝑺𝒕𝒓𝒂𝒑𝒔 𝒄𝒍𝒐𝒔𝒆𝒅

∝√

𝟏
𝟏
+
𝛕𝒅 𝝉𝑹𝑮𝟏
𝟏
𝟏
𝟏
+
+
𝝉𝒅 𝝉𝑹𝑮𝟏 𝝉𝒕𝒓𝒂𝒑𝟏

(13)
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Figure 9. Reduction in in-field diode measurement with decreasing delivered dose rate is plotted for (1) 3x3
and 20x20cm MapCHECK2 fields, (2) a 25x25 ArcCHECK arc, and (3) 23 10x10 arcs. Reduction is
normalized to 570 MU/min.

To better understand the clinical effect of dose rate dependence on AC QA, MC and CS
calculated doses were compared to AC measurement for each diode in an open 25x25cm arc
for both 70 and 570 MU/min dose rates. Plan-CS vs. AC percent dose differences were -2.1 ±
0.5% and -0.7 ± 0.5% at 570 and 70MU/min dose rates respectively. In comparison, Plan-MC
vs. AC percent dose differences were 0.3 ± 0.8% and 1.7 ± 0.8%. Interestingly, because MC
doses were generally higher than CS doses and higher dose rates resulted in greater
measurement, MC dose differences were smaller for high dose rates, while CS dose differences
were smaller for low dose rates. In comparison to AC QA, LF QA should be invariant with
respect to dose rate. To verify whether this is indeed the case, percent difference in 70MU/min
vs. 570MU/min LF-MC dose was calculated for the same 25x25cm arc; per-diode dose
difference was 0 ± 0.85% and 0 ± 0.21% when calculated with 1% and 0.25% MC dose
uncertainties, respectively. This shows that whereas AC QA is sensitive to dose rate and could
yield false positives/negatives, LF QA does not have this issue.
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Table 4. 10x10 arcs of varying gantry excursions and MU

Gantry Start/Stop/Excursion
-90 / -60 / 30
-90 / -30 / 60
-90 / 30 / 120
-90 / 90 / 180

MU
10, 20, 35, 50, 100
20, 40, 70, 100, 200
20, 40, 80, 140, 200, 400
20, 40, 60, 120, 210, 300, 600

2.3.3.2 Out-of-Field Discrepancy: Energy Effect
Fig. 10 displays percent difference in calculated (Plan-CS and LF-MC) versus AC
measured diode dose as a function of off-axis distance for a 10x10cm 358° arc. For the in-field
region, measurement and calculation agreed well. In the penumbral region, significant dose
difference is seen. Penumbral differences are attributed to imperfect geometry (e.g. imperfect
linac isocentricity, imperfect leaf calibration, and setup error) and physical diode limitations
(e.g. finite size), as well as the two issues discussed in the next paragraph.
Out-of-field, calculation is much lower than measurement.

This disagreement is

comprised of two major components. First, the calculation model could be underestimating
collimator scatter and head leakage at greater off axis distances. For CS, this is typical of many
institutions and is known to be the case at our institution as well. 84-88 Second, diodes could be
over-responding to the low energy patient-scattered photons. Rickner et. al theorizes 30% and
70% increases in diode sensitivity to 0.5MeV and 0.1MeV photons. 58 The typical energy range
of patient-scattered photons is right in this range. 89 Thus, one can expect an approximate 50%
over-response to low energy photons, and an approximate 30% net over-response after
multiplying by the low energy component of the fluence. Figure 10 illustrates the percent
difference in calculated dose (Plan-CS and LF-MC) and the ArcCHECK measured dose as a
function of off-axis distance for a 10x10 cm2 358° arc. The MC results of are in good agreement
with Rickner et al.; a relative 10-30% over-response by out-of-field diodes is concluded for this
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10x10 cm2 field. It is important to note this is for a 0% dose threshold. A 10% dose threshold
is explored below to determine clinically relevant effects only.

Figure 10. Calculated vs. measured dose differences are plotted as a function of axial distance from
isocenter for a 10x10 arc using a) Plan-CS and b) LF-MC calculated doses.

Field size plays a critical role in determining the energy spectrum of photons at each
diode. Here, the effect of field size on energy spectrum, and subsequently diode sensitivity was
studied. Three static 200MU arcs (2x2 cm2, 10x10 cm2, 25x25 cm2) were delivered on the
ArcCHECK phantom. Fig. 11a and Fig. 11c plot histograms of percent difference in calculated
versus measured diode dose for each field size and for CS and MC respectively. Fig. 11b and
Fig. 11d plot the same histograms with a 10% dose threshold applied. Histograms consisted of
a tight primary peak and prolonged ‘spectral’ out-of-field distribution for both CS and MC.
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Figure 11. Histograms of percent diode dose difference (calculated vs. measured) for CS and MC with
respect to ArcCHECK measurement. The left plots (a, c) utilize no threshold, while the right plots (b, d)
utilize a 10% threshold based off the maximum measured dose.

As discussed previously, this ‘spectral’ distribution results from inaccurately calculated
collimator and head leakage as well as diode over-response to patient-scattered radiation. Dose
differences increased with decreasing field size. By shrinking the field, the distance from the
field edge to distal diodes increases. This results in more medium to scatter off and thus a softer
photon spectrum and greater diode over-response. As illustrated by the relative positions of
their out-of-field distributions as well as the integral area of these distributions, MC yielded
better agreement with out-of-field measurement than CS. For the 2x2 cm2 field size, a good
portion of CS’s spectral distribution is centered around -90%. This corresponds to a 10 times
greater measured versus calculated dose.

This massive difference is in part due to an
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underestimation of out-of-field dose by the CS method, but also largely due to the extremely
low dose – a low absolute dose will yield a larger relative dose difference. For the 2x2cm MC
field, measurement is 70% higher than calculation. Given the diode over-response values
mentioned in 3.3.2, 70% over-response is reasonable. It is important to note that some portion
of this discrepancy will be due to calculation inadequacies.
Despite the very large discrepancies seen in Fig. 11a/c, when a standard 10% dose
threshold is applied (Fig. 11b/d), much of this out-of-field component is eliminated. For
instance, for the 2x2cm field where the absolute quantity of patient scatter is minimal, there is
a miniscule out-of-field distribution. Thus, diode energy dependence is going to result in very
few failing diodes. However, for the 10x10cm field where the absolute magnitude of patient
scatter is greater, the number of failing out-of-field diodes that are above the measurement
threshold is more noticeable - energy effects are seen on the order of 3-5% of the maximum
measured dose. Although systematic uncertainties due to energy and dose rate will cancel out
to some degree, when compared to standard 2-3% gamma criteria, 3-5% over-response to lower
energy radiation remains worrisome.
2.3.3.3 Delivery Complexity
Static fields/arcs with a wide variety of field sizes were delivered onto the ArcCHECK
phantom and log files reconstructed using Monte Carlo. LF-MC calculated dose is compared
to AC diode measurement using MPDD and MAPDD along with an 85% dose threshold. Fig.
12a and 12b display MPDD and MAPDD respectively as a function of field size (FS X · FSY).
Smaller fields yielded greater MAPDD values, indicating greater LF-MC vs. AC disagreement
for smaller field sizes. Negative and positive MPDD values were seen because an 85% dose
threshold will include some field penumbra.

Consequently, any small shift in diode position
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due to setup error or MLC position due to leaf calibration error can result in large differences
between calculation and measurement. Depending on the position of the diode with respect to
CAX (e.g. ±x̂/ŷ), direction of setup error, and direction of leaf calibration error, measured diode
dose may increase or decrease with respect to calculation.

Figure 12. LF-MC and AC doses are compared for varying field sizes using an 85% dose threshold. a)
Mean Percent Dose Difference (MPDD) and b) Mean Absolute Percent Dose Difference (MAPDD) are
plotted against FSx*FSy for all the aforementioned fields in Section 2.2.3.

Delivering various combinations of abutting fields onto the ArcCHECK phantom,
calculated (LF-MC, Plan-MC, Plan-CS) vs. AC measured dose difference was evaluated as a
function of segment size and quantity. Table 5 displays MPDD values for each static and arc
field arrangement using both 10% and 85% dose thresholds. As the number of segments
increased, Plan-CS increasingly deviated from measurement (max 13%). This Plan-CS dose
difference likely occurs due to the out-of-field dose mismatch seen between CS and AC in
section 2.3.3.2. This discrepancy is seen not only for the 10%, but also the 85% dose threshold.
This is because what is considered out-of-field for one segment may be considered in-field for
the combined 12x12cm field. Plan-MC and LF-MC matched measurement within a few percent
for all cases. LF-MC and Plan-MC deviated from measurement by 1.42 ± 1.2% and 1.56 ± 1.2%
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on average respectively. This shows improvement by accounting for delivery errors was only
0.14%.
Table 5. MPDD (mean percent dose difference w.r.t AC) values are displayed for various field
complexities, static and arc fields, and for 10% and 85% dose thresholds.

Field(s) →
Threshold ↓
LF-MC
10%
85%
Plan-MC 10%
85%
Plan-CS
10%
85%
LF-MC
Plan-MC
Plan-CS

10%
85%
10%
85%
10%
85%

12x12cm

4 6x6cm

1.0 ± 11.0
-1.1 ± 1.4
3.4 ± 10.2
1.4 ± 1.4
-0.2 ± 11.6
-1.5 ± 1.6

-0.4 ± 11.1
-2.7 ± 2.2
2.3 ± 12.2
-0.1 ± 1.6
-2.1 ± 13.6
-4.3 ± 3.5

0.3 ± 6.2
0.2 ± 1.3
2.7 ± 5.9
2.8 ± 1.3
-0.2 ± 11.6
-1.4 ± 1.6

-2.4 ± 6.6
-1.8 ± 1.6
-0.2 ± 6.6
0.6 ± 1.6
-2.1 ± 13.6
-4.2 ± 3.5

9 4x4cm
16 3x3cm
Static Fields
0.2 ± 10.5
0.4 ± 9.4
-1.2 ± 2.4
-0.8 ± 3.3
0.9 ± 9.3
-0.5 ± 8.5
-0.5 ± 1.6
-1.9 ± 3.0
-3.6 ± 10.7
-6.7 ± 9.2
-4.6 ± 3.5
-6.9 ± 3.0
Arcs
-2.7 ± 8.2
-3.8 ± 10.3
-0.9 ± 2.0
-0.1 ± 1.9
-2.1 ± 8.0
-3.7 ± 10.2
-0.1 ± 1.9
-0.3 ± 1.9
-3.6 ± 10.6
-6.6 ± 9.2
-4.6 ± 1.9
-6.9 ± 3.0

36 2x2cm
4.5 ± 17.4
1.8 ± 4.8
2.3 ± 16.6
-1.0 ± 3.6
-11.4 ± 13.5
-7.6 ± 2.3
-0.5 ± 21.5
-1.6 ± 6.2
-0.7 ± 21.6
-3.6 ± 3.2
-13.0 ± 24.8
-11.7 ± 2.9

2.3.4 Comparing LF QA & AC QA
Gamma pass rates were calculated for each of 22 clinical beams and each dose-pair
shown in Table 6 using a 10% dose threshold. Comparing #3 to #1, we saw lower LF-CS than
Plan-CS pass rates, suggesting even 1° control point spacing was insufficient. Comparing #4
to #2, reconstructive accuracy was evaluated for the full 25Hz log file; pass rates were identical
or improved for 17/18 (2%/2mm) and 14/18 arcs (1%/1mm). High pass rates for #5 and #6
indicate both dose calculation differences and machine delivery errors were small.
results (#7) were similar to AC QA results (#1/2).
Table 6. 2%/2mm and 1%/1mm gamma pass rates are shown for each dose-pair.

#
1
2
3
4

Comparison
Plan-CS vs. AC
Plan-MC vs. AC
LF-CS vs. AC
LF-MC vs. AC

2%/2mm
97.5 ± 1.6%
96.5 ± 4.2%
97.0 ± 2.4%
97.3 ± 3.2%

1%/1mm
81.6 ± 6.5%
78.1 ± 9.9%
79.2 ± 8.1%
78.9 ± 10.3%

LF QA
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5
6
7

Plan-MC vs. Plan-CS
LF-MC vs. Plan-MC
LF-MC vs. Plan-CS

99.0 ± 2.4%
99.6 ± 0.4%
96.8 ± 5.1%

85.0 ± 8.2%
91.0 ± 2.7%
76.3 ± 11.6%

Values are calculated for the same 22 beams for each plan pair in Table 7 Comparison
#5 isolates differences in dose calculation method; MC and CS agreed within 1-2%.
Comparisons #6/7 isolate delivery errors for CS and MC respectively; the effect of delivery
error was ~0±1%. Comparing #3 to #1 and #4 to #2, the effects of delivery error are again seen
to be very small for this Agility system. #2/4/5 show MC dose was systematically 1.2% higher
than CS dose when utilizing an 85% dose threshold. This is believed to result from slight MC
vs. CS beam model differences stemming from how CS dose is normalized to a 10x10cm field
at 10cm depth and MC is not. Rather, the MC beam model was simply designed to best match
calculation to measurement for the greatest amount of PDDs and dose profiles. Accounting for
both delivery error and calculation difference, comparison #8 is this study’s standard LF QA
comparison. Summing systematic differences linearly and statistical differences in quadrature,
#8 equals #5 plus #7 for both dose thresholds. Eliminating phantom error sources resulted in
substantially reduced uncertainty; values for #5-8 were ~0.8 ± 1.2% lower than #1-4. We
conclude phantom-based uncertainty is ~0.8 ± 1.2%. It is important to note that phantomdependent uncertainty includes not only measurement and setup uncertainties, but also any
potential beam inconsistencies due to imperfect machine QA that the log file does not track.
Gamma and statistical analyses both led to the same conclusions.
Table 7. Global percent diode dose differences (mean ± σ) are displayed for various plan pair comparisons
and for both 10% (standard) and 85% (target) dose thresholds.

Comparison
#1 Plan-CS vs. AC
#2 Plan-MC vs. AC
#3 LF-CS vs. AC

10% Threshold
0.8 ± 1.8%
1.0 ± 1.8%
1.0 ± 1.8%

85% Threshold
0.8 ± 2.6%
2.1 ± 2.5%
0.8 ± 2.6%
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#4
#5
#6
#7
#8

LF-MC vs. AC
Plan-MC vs. Plan-CS
LF-CS vs. Plan-CS
LF-MC vs. Plan-MC
LF-MC vs. Plan-CS

1.0 ± 1.7%
0.2 ± 1.1%
0.2 ± 1.0%
0.1 ± 0.9%
0.2 ± 1.3%

2.1 ± 2.5%
1.2 ± 1.7%
0.4 ± 1.4%
0.0 ± 1.3%
1.2 ± 2.1%

2.4 Summary
As discussed briefly in the introduction, there exist distinct advantages and
disadvantages of the two QA systems. The key advantage of ArcCHECK is that it directly
measures dose; physicists can trust measurement within the ranges of uncertainty set forth in
this study. However, it is difficult to determine the cause of failing pre-treatment QA. In
comparison to AC QA, LF QA is unaffected by phantom-dependent uncertainties and capable
of isolating the cause of dose difference. The downside of LF QA is that it relies heavily on
machine QA and accurate dose calculation. Log file reconstructed dose would be more accurate
if beam limiting device (BLD) calibration was carried out more often. Reconstruction accuracy
could be further improved by better maintaining beam output and symmetry whether through
more frequent QA or tighter tolerances. Furthermore, LF QA is unable to account for dose
calculation differences when utilizing the same dose calculation method as the TPS. Thus, LF
QA should ideally utilize an independent dose calculation method that has been thoroughly
vetted as detailed in TG-106.90 In the case of dose deviance between the two methods,
ArcCHECK can be utilized as a second check. Assuming a non-MC TPS dose calculation
engine, Monte Carlo is well suited for LF QA. Conventionally, MC is deemed accurate, but
slow. However, reconstructing every log file sample with no increase in cost, LF-MC QA is
not only accurate, but exceptionally fast.

Once properly setup, LF-MC QA is a fully

automatable patient-specific QA technique that can quickly and accurately calculate per-
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fraction delivered dose. However, given the increased reliance on machine QA and dose
calculation accuracy, LF QA should at least initially be used only as a supplement to current
QA systems.
2.5 Conclusion
In Chapter 2, LF QA is assessed as a potential supplement or potential replacement of
ArcCHECK QA. First, preliminary validations were carried out to assure there are no flaws in
the work that we are carrying out here. The beam models and MLC calibration were both
verified to be accurate. For LF-CS QA, varying control point spacings were investigated in
order to determine the optimal number of log file samples that should be utilized. Utilizing
control point spacing greater than 1° resulted in substantially degraded dosimetric accuracy.
LF-CS QA utilizing 1° control point spacing and LF-MC QA utilizing the full 25Hz log file
both yielded equivalent results to AC QA. Next, the ability of diodes to accurately measure
dose was investigated. Calculation and ArcCHECK measurement differed by up to 1.5% infield due to variation in dose rate and up to 5% out-of-field. For highly segmented experimental
plans, despite CS calculation deviating by as much as 13% from AC measurement, Plan-MC
and LF-MC doses generally matched AC measurement within 3% (mean 1.56% and 1.42%
respectively). Finally LF-CS QA and LF-MC QA as carried out on the phantom geometry was
carried out and compared to conventional AC QA. Carrying out AC QA and LF QA for 22
clinical VMAT arcs, phantom-dependent, calculation method-dependent, and delivery errordependent dose uncertainties were found to be 0.8 ± 1.2%, 0.2 ± 1.1%, and 0.1 ± 0.9%
respectively.

It follows that by eliminating phantom-dependent uncertainty, LF QA is

theoretically more accurate than AC QA. However, none of the doses utilized (AC, MC, CS)

55

can truly be considered a gold standard. Without a gold standard, we merely conclude that LF
QA and AC QA offer similar dosimetric accuracy.
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CHAPTER 3 LF QA FOR TREATMENT PLANNING AND DELIVERY QA: PART 2
– PATIENT ANATOMY
3.1. Introduction
In the previous chapter, log file doses were reconstructed on the ArcCHECK geometry.
Ultimately, LF-MC QA and LF-CS QA were deemed to be equivalent to ArcCHECK QA given
standard TG-40 and TG-142 machine QA protocols are carried out. In this chapter, LF QA is
instead carried out on the patient specific anatomy.

DVH-based metrics as well as the

aforementioned TCP formulation are used to evaluate the differences between the calculated
treatment planning dose and the dose reconstructed using LF-MC QA. In addition, LF-MC QA
is utilized as a treatment planning QA tool.
There are three key objectives of this study: (1) to establish the accuracy of LF-MC QA, (2)
to compare the performance of patient-specific LF-MC QA with phantom-based QA, and (3)
to quantify the causes of discrepancy determined by LF-MC QA. To achieve objective 1, the
accuracy of MC dose calculation is assessed versus commissioning data as well as phantom
measurement setups. To fulfill objective 2, LF-MC QA results on the patient anatomy are
compared to clinical ArcCHECK results. For objective 3, dose discrepancy is broken down
into delivery error, gantry discretization difference, and dose calculation difference. Dosimetric
discrepancy due to calculation method was further broken down as a function of beam
complexity and patient heterogeneity. Although LF-MC QA on the patient anatomy is the main
focus of this study, Monte Carlo may not be available for every institution. Thus, delivery error
was also assessed using LF-CS QA.
3.2. Materials & Methods
3.2.1. Dose Calculation Validation
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Both dose calculation methods were first thoroughly validated with respect to measurement.
Calculation was first investigated for square fields as delivered on a the homogeneous IBA
Blue Phantom water tank. It is mandatory that calculation methods agree with measurement
well for these simple square fields in a homogeneous medium. If they don’t agree well for
square fields and a homogeneous geometry then they will not agree well for more
complicated plans delivered on heterogeneous patient anatomy. Next, more complicated
clinical fields were delivered onto a homogeneous solid water stack. Measurement was
compared to calculation to assure that we are able to accurately deliver complicated fields.
However, neither of these tests assess the ability of CS and MC to accurately calculate dose in
a heterogeneous environment, thus CS and MC calculation was also compared to
measurement in a heterogeneous cork phantom for square fields.
3.2.1.1. Water Tank Measurement Data – Square Fields
It is important to note that the MC beam model was redone using a newer set of
measurement data (M2) since Chapter 2. Thus, for this paper, CS and MC are commissioned
using two different, but similar, sets of measurement data – M1 and M2 respectively. To
investigate the quality of the beam models the following comparisons were made. CS and MC
were compared to M1 and M2 respectively. M2 was compared to M1 to make sure the
measurements were accurate within approximately 1%. Lastly, MC and CS were compared.
M2 was acquired in the same way as M1 except for two key differences. First, output
factors less than 5x5cm2 and PDDs less than 2x2cm2 were acquired using a PTW60019
microDiamond. Second, M1 was affected by a software bug that M2 was not affected by. This
bug in IBA’s OmniPro-Accept software v7.3-7.4b resulted in water scans in which background
may not have been subtracted, compressing and offsetting the vertical scale of the data.
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Unfortunately, it was impossible to be sure which profile measurements were affected by this
bug. It follows that some M1 cross-beam profiles had inflated tails. Ideally, the CS beam
model would be redone using M2, however such an undertaking is outside of the scope of this
dissertation. Furthermore, the CS beam model parameters were not affected by this discrepancy.
Per-field comparison metrics included (1) absolute percent difference in output factor,
(2) mean absolute percent global difference in PDD from 0-35cm, (3) mean absolute percent
local difference in in-field dose, (4) mean absolute percent global difference in out-of-field
(<10%Dmax) dose, (5) mean absolute distance-to-agreement in the penumbra (80%-20%), (6)
mean absolute difference in penumbra width, and (7) mean absolute difference in field width
(50%-50%). Due to insufficient scan length, penumbra and out-of-field data for the 40x40cm
field were not analyzed.
3.2.1.2 Solid Water Phantom Measurement Data – Clinical Fields
To determine the accuracies of the two calculation methods, point doses measurements were
taken and compared to both CS and MC calculation. First, TG-119 measurements were carried
out.49 TG-119 cases included: prostate, H&N, C-shape (hard), H&N with integrated boost
(HNSIB), and prostate with lymph nodes (PLN). It is noted that the latter two cases are
additional cases provided to us by Henry Ford Health System that are not part of the TG-119
publication. HNSIB and PLN were included because they are more difficult than their H&N
and prostate counterparts and thus push the QA harder. It is important to QA more difficult
treatment cases. Although these two cases are not part of TG-119 for the rest of this chapter
they will be included as if they are. Two measurement positions were utilized for each test, one
at the center of the target ROI and one in an out-of-field organ-at-risk (OAR). In total, ten
measurements were compared to ten MC calculations and ten CS calculations.

All
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measurements were taken using a 0.125cc Wellhofer IC-10 ion chamber inserted into a
30x30x15cm stack of solid water. As recommended in TG-119, dose to charge ratio was
determined by delivering 10x10 AP/PA fields onto the solid water stack and comparing
measurement to dose calculation. This dose per charge metric was calculated for both dose
calculation methods; the difference in the two dose per charge factors was 0.3%. Finally, results
were compared to those found in TG-119.
In addition to the standard TG-119 cases, 11 clinical VMAT plans (22 arcs) were delivered
onto the same solid water stack. These plans were selected to cover a range of MC – CS dose
variations. Measurement points were selected per plan to be in a high dose, low dose gradient
regions. The measurement point was confined to the central 18x18x3cm of the slab to ensure
6cm of medium to laterally scatter off of at all gantry angles. The same dose per charge factors
were utilized as in the TG-119 measurements. For Monte Carlo, the solid water was overridden
to a density of 1.035. This density was found to maximize the agreement between measurement
and Monte Carlo for the specific solid water material composition utilized. A dose grid
resolution of 4mm was utilized to match the diameter of the ion chamber utilized. Monte Carlo
statistical uncertainty was set to 0.25%. A variety of density overrides were analyzed for
Convolution Superposition, however, ultimately, utilizing no density override was found to
yield the greatest agreement between CS and measured doses.
3.2.1.3 Cork Phantom Measurement Data – Square Fields
Heterogeneous dose calculation accuracy was assessed for both CS and MC calculation
with respect to ion chamber measurement in a “lung phantom.” The lung phantom utilized in
this study consisted of 10cm of composite cork sandwiched between 6cm (entrance) and 6cm
(exit) of solid water. Composite cork is known to be dosimetrically equivalent to ICRU-44
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lung tissue.91 The solid water slabs on either side of the cork act like the front and back of the
patient respectively. The phantom was imaged while the ion chamber was inserted into the cork.
In the resulting CT images, the cork phantom had a mean CT density of -897HU. To account
for various ion chamber positions, CT image slices were virtually shifted and re-imported into
Pinnacle3. The ion chamber was inserted at 12 depth positions along the central axis after
accounting for a 1.3mm shift in dose reference point relative to the chamber surface. [1.4, 6.5,
7.45, 8.4, 9.35, 10.3, 11.25, 12.2, 13.15, 14.1, 16, and 17cm depths]. The ion chamber utilized
was a TN-34045 parallel plate ion chamber. Calculation and measurement were compared for
both 4x4 cm2 and 10x10 cm2 square fields. Due to the large active volume of the parallel plate
chamber, smaller field sizes were not investigated.
3.2.2 LF-MC and LF-CS QA on the Patient Anatomy
Log files are acquired using Elekta’s Log File Convertor for Integrity R3.2. The log
files record linac delivery parameters (dose rate, gantry/collimator angle, leaf/collimator
positions, MU) every 40ms. For this study, an Elekta Infinity linac equipped with the Agility
beam-limiting device was utilized. Plans were selected from previously treated patients that
were planned and optimized using the Pinnacle3 treatment planning system.
LF QA was assessed on the patient anatomy using both MC and CS dose calculation
algorithms. Four dose distributions were utilized in this study. Plan-CS is the clinical treatment
plan dose that was planned and optimized in Pinnacle3 v14.0 using convolution-superposition.
The clinical Plan-CS doses were planned using a 4° control spacing.

Plan-MC is the

corresponding Monte Carlo dose calculated using the exact same plan as Plan-CS. LF-CS dose
is calculated using the linac log file and Pinnacle’s convolution-superposition. Lastly, LF-MC
dose is calculated using the linac log file and Monte Carlo. The log file dose reconstruction
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methodologies match those explained in chapter 2. For LF-CS, log files are selected to achieve
as close to 1° control point spacing as possible. This is done by converting log file samples into
control points in a dynamic arc field. For LF-MC, every log file sample with non-zero MU is
converted into a control point in a dynamic arc field. MC doses were calculated using 1%
statistical dose uncertainty. CT-to-density table and ROI override information was the same
for both Pinnacle convolution-superposition (CS) and SciMoCa (MC) dose calculation
algorithms. All doses were calculated using the same 3mm dose grid resolution that is used to
calculate Plan-CS doses clinically at our institution.
The patient-specific LF-MC QA tool presented in this study is designed to verify the
accurate calculation and delivery of dose on each patient’s unique heterogeneous anatomy.
First, accurate dose calculation was verified. LF-MC QA utilizes three key dose comparisons.
Comparing Plan-MC to Plan-CS, dose discrepancy resulting from dose calculation method
differences was isolated. When comparing dose calculation methods, all comparisons were MC
with respect to CS. Comparing LF-MC to Plan-MC, dose discrepancy due to delivery error
was isolated. Lastly, LF-MC vs. Plan-CS was analyzed in order to account for the combined
effects of delivery error and dose calculation. However, because delivery error was found to
be near-zero, the combined effects were similar to the effect from the dose calculation
discrepancy and used for the rest study.
The LF-CS QA tool presented in this study is simpler than the LF-MC QA tool in that it is
only capable of catching delivery error; calculation accuracy is not verified. However, it is not
as simple as comparing LF-CS to Plan-CS. In Chapter 2, it was shown that LF-CS QA ought
to utilize a control point spacing no larger than 2° (1° is preferred). However, the clinical
treatment dose, Plan-CS, was calculated with a 4° control point spacing. Thus, when comparing
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LF-CS doses to Plan-CS doses, delivery error is not truly being isolated. In order to assess this
addition “gantry discretization difference” Plan-CS(4°) control points were linearly interpolated
in Pinnacle and Plan-CS(2°) dose calculated. Pinnacle does not easily allow for further
interpolation, thus Plan-CS(1°) was not calculated. In total, three doses were compared in order
to quantify the effects of gantry discretization difference: LF-CS(1°), Plan-CS(2°), and PlanCS(4°). Two comparisons were carried out. First, LF-CS(1°) dose was compared Plan-CS(4°)
dose. This dose difference is due to delivery error as well as gantry discretization differences.
Second, LF-CS(1°) was compared to Plan-CS(2°). This dose difference is the same as before
except with reduced gantry discretization difference. The goal of studying the effects of gantry
discretization is to determine if Plan-CS(4°) needs to be interpolated to Plan-CS(2°) for some
or all LF-CS QA cases. Whereas clinical Plan-CS dose on the patient anatomy is calculated
using 4° control point spacing, in Chapter 2 on the ArcCHECK geometry, all Plan-CS doses
were clinically calculated using 2° control point spacing. It is important to note that MC does
not suffer from discretization error. MC simulates millions of particle histories at all possible
continuous gantry angles for both Plan-MC and LF-MC. Thus, LF-MC vs. Plan-MC dose
difference is an accurate quantification of delivery error.
42 patients (85 treatment fields) were selected for this study based on the following
criteria. First, plans must have been delivered on the Elekta Agility machine so that linac log
files could be acquired. Second, all investigated fields were dynamic arc deliveries. In total,
12 head and neck, 6 lung, 6 breast, 5 brain, 4 esophageal, 3 mediastinum, 2 prostate, 2 spine, 1
stomache, and 1 axillary node patients were analyzed.
LF-MC QA utilizes the following metrics to evaluate the effects of planned patient dose
discrepancy. DVH-based metrics included PTV Dmean, PTV D99%, PTV D95%, and PTV D1%.
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These metrics were also calculated for GTV ROIs. Site-specific organ at risk (OAR) constraints
were utilized as gathered from TG-101 and site-specific RTOG protocols.7 DVH-based metrics
were evaluated per-plan. In addition to DVH-based metrics, 3%/2mm gamma pass rates were
calculated on the patient anatomy using both 10% (standard) and 85% (target approximation)
dose thresholds. Lastly, tumor control probabilities (TCP) were calculated per plan as presented
by Niemierko et al.23 TCP was calculated using GTV when available and CTV when not. A
study by Okunieff et al. shows that γ50 values can vary significantly between treatment site. 92
Treatment site-specific TCD50 and γ50 values were acquired from a variety of
publications.92-95 The following treatment site-specific γ50 values were utilized: H&N 1.03;
brain 0.75; lung 0.57; esophagus 1.03; breast 1.03; mediastinum 0.41; spine 0.41; stomache
0.71; prostate 0.74. TCD50 values were selected based upon the staging of each patient’s
individual treatment. All LF-MC QA metrics were calculated per-plan.
3.2.3 Dose Discrepancy (MC vs CS)
In Chapter 1, the main sources of calculation difference between Monte Carlo and
collapsed-cone convolution-superposition were stated as being complexity and heterogeneity.
Dosimetric differences in the two calculation methods is assessed as a function of beam
complexity and patient heterogeneity.
3.2.3.1 Beam Complexity
Monitor units (MU) per prescription dose (Rx) is a standard metric for quantifying beam
complexity.96 Variation in dose due to calculation difference was evaluated as a function of
MU/Rx on the patient anatomy for both target and external (outer contour around the patient
skin) ROIs.
3.2.3.2 Patient Heterogeneity
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Monte Carlo is known to more accurately model anatomical heterogeneities than
convolution-superposition algorithms.14 To quantify this effect and potentially explain the
dosimetric variation seen between the two algorithms, 10 patient plans (5 lung and 5 H&N)
were recalculated with the entire patient volume being overridden to unit mass density. Dose
variation was analyzed as a function of tumor position relative to air gaps as well as bony
anatomies.
3.3 Results
3.3.1 Dose Calculation Validation
3.3.1.1 Water Tank Measurement Data
Table 8 displays validation results for the two dose calculation methods and two sets of
measurement data. From the first two data columns we see that both calculation methods yield
clinically acceptable results.90 MC consistently agreed within 1% and 1mm of the M2
measurement data.

Similarly, CS consistently agreed within 1% and 1mm of the M1

measurement data. Furthermore, the two sets of measurement data were also in good agreement
with each other. The largest difference between the two sets of measurement data was seen out
of field. This difference is attributed to a since-fixed software bug in IBA’s OmniPro-Accept
software where background was not being subtracted despite the software saying it had been.
M1 contained this bug while M2 did not, resulting in higher tails. Lastly, MC and CS generally
agreed within 1% / 1mm of each other. In comparing the two calculation methods, the greatest
difference was found to be in the in-field region with a variation of 1%. Thus, for square-fields
and a water tank, all measured and calculated data generally agreed within 0.5% or 0.5mm and
almost always agreed within 1.0% or 1mm.
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Table 8. Beam model validation results are summarized. *CS output factors are exactly determined from
measurement.

Output Factor
PDD
Penumbra DTA
Beam Width
In-Field
Out-of-field

MC vs M2
0.15 ± 0.13%
0.41 ± 0.17%
0.23 ± 0.11mm
0.64 ± 0.62mm
0.58 ± 0.19%
0.20 ± 0.16%

CS vs M1
0*
0.52 ± 0.13%
0.34 ± 0.16mm
0.60 ± 0.27mm
0.60 ± 0.15%
0.33 ± 0.41%

M2 vs M1
0.25 ± 0.31%
0.38 ± 0.19%
0.50 ± 0.89mm
0.63 ± 0.56mm
0.24 ± 0.17%
0.80 ± 0.09%

MC vs CS
0.25 ± 0.31%
0.64 ± 0.28%
0.45 ± 0.17mm
0.67 ± 0.32mm
1.06 ± 0.48%
0.38 ± 0.25%

3.3.1.2 Solid Water Phantom Measurement Data
Per-plan percent differences in calculated vs. measured doses for the ten TG-119
measurement points displayed in Table 9. Percent differences are normalized relative to the
prescribed doses. In general, MC agreement with measurement was superior to that of CS. CS
agreed with measurement within 3% for 7/10 cases. Disagreement as large as -4.6% was seen
for the in-field C-Shape(Hard) case. In comparison, MC agreed with measurement within 3%
for all cases and within 2% for 8/10 cases.
Table 9. TG-119 results are tabulated per treatment site for both high dose and low dose measurement
regions as well as both CS and MC dose calculation methods.

H&N
C-Shape(Hard)
Prostate
Prostate + LN
H&N SIB

Percent Difference in Calculated vs. Measured Dose
Target Measurement Point
OAR Measurement Point
CS
MC
CS
MC
2.4%
0.9%
4.5%
0.4%
-4.6%
-1.2%
3.1%
-2.7%
0.3%
1.1%
1.7%
2.2%
-0.3%
0.9%
1.1%
-0.6%
1.0%
-1.2%
-1.3%
-1.7%

As displayed in Table 10, TG-119 results found herein are compared to results found in
the actual TG-119 task group report. High dose measurements are addressed first. Whereas in
TG-119, a confidence level of 4.5% is reported, CS and MC confidence levels were 5.3% and
2.4% respectively. Next, low dose TG-119 results were addressed. Whereas in TG-119, a
confidence level of 4.7% is reported, confidence limits for CS and MC were 6.1% and 4.2%
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respectively. It is important to reiterate that the TG-119 literature results include some simpler
treatment sites and IMRT deliveries instead of the VMAT deliveries utilized herein.
Table 10. TG-119 results from this study are compared to literature for both high dose and low dose
regions.

Mean Difference
Mean Absolute
Difference
Confidence Limit
Mean Difference
Mean Absolute
Difference
Confidence Limit

TG-119
CS
High Dose Region
-0.2 ± 2.2% -0.2 ± 2.6%
0.9%
1.7%

MC

4.5%
5.3%
Low Dose Region
0.3 ± 2.2% 1.8 ± 2.2%
1.1%
2.3%

2.4%

4.7%

4.2%

6.1%

0.1 ± 1.2%
1.0 %

-0.5 ± 1.9%
1.5%

Per-plan percent difference in calculated vs. measured dose was calculated for eleven
clinical cases. On average, MC agreed within -0.04 ± 1.61% of measurement. Absolute
agreement was 1.20 ± 1.02%. In comparison, CS agreed with measurement within 1.65 ±
1.86%. Absolute agreement was 1.81 ± 1.69%. For all but one case (#4), MC agreed with
measurement within 2%. CS agreed with measurement within 3% for all but the same case
(#4). In general, MC outperformed CS; the MC confidence limit was 3.2% as opposed to the
5.3% of CS.
3.3.1.3 Cork Phantom Measurement Data
CS and MC calculation were compared to Markus chamber measurement at various
cork depths in the phantom. Calculated MC and CS PDDs are plotted against ion chamber
measurement for 4x4 and 10x10 fields in Fig 13. On average, CS agreed with measurement
within 4.3 ± 2.6% and 2.1 ± 1.7% for 4x4 and 10x10 square fields at the measurement points
shown. MC agreement was 1.3 ± 1.3% and 0.5 ± 0.4% for the same fields. Monte Carlo
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agreement with measurement was better than that of CS especially for measurement points
deeper into the cork. These results are as expected. As discussed in Chapter 1, Monte Carlo is
expected to better calculate heterogeneous dose.

Figure 13. Calculated CS and MC PDDs are calculated and compared to ion chamber measurement in a
water-cork-water phantom for 10x10 and 4x4 square fields.

In this section, the dosimetric accuracy of CS and MC was evaluated with respect to
measurement for square fields as well as clinical VMAT fields as calculated on both a water
tank and solid water phantom. The accuracy of these dose calculation methods in a
heterogeneous environment was also assessed via the use of a heterogeneous cork phantom.
For square fields in a homogeneous water tank, both CS and MC beam models were both
accurate within 1% where these values are systematic difference with respect to measurement
plus one standard deviation. For square fields in the cork phantom, CS and MC were accurate
within 2.5% and 1.0% respectively. For clinical fields delivered on a solid water stack, CS
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and MC were generally accurate within 3% and 2% respectively. It is important to note that
these values are all within the goal of having a 3% dose calculation accuracy. This
demonstrates that both dose calculation methods are doing a good job. Furthermore, it
demonstrates that the beam models are high quality.
3.3.2 LF-MC and LF-CS QA on the Patient Anatomy
Fig. 14 displays histogram plots of variation in PTV Dose. Subfigure 14a illustrates percent
variation in calculated dose for the PTV. Variation in dose due to calculation difference (i.e.
dose calculation method) is broken down by treatment site and displayed in Table 11. Subfigure
14b displays the same data except for delivery error instead of calculation difference. Dose
discrepancy due to dose calculation method was substantial. Percent differences in calculated
dose for PTV Dmean, D99, D95, and D1 values were -3.4 ± 1.9%, -4.6 ± 2.8%, -4.5 ± 2.1%, and 1.2 ± 2.8% (negative differences mean MC dose is lower than CS dose). Variation in GTV/CTV
dose was generally a relative 5-10% lower than PTV dose variation. In comparison, dose
variation due to delivery error was minimal. Dose variation was consistently within 1% for
each of the PTV and CTV metrics. Percent differences in dose due to delivery error for PTV
Dmean, D99, D95, and D1 were -0.08 ± 0.08%, 0.02 ± 0.2%, 0.01 ± 0.12%, and -0.15 ± 0.17%.
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Figure 14. Histogram plots of percent difference in key PTV DVH metrics as a result of a) calculation
difference, b) delivery error.
Table 11. Target and OAR dose variation due to calculation difference (MC – CS) is quantified per
treatment site. Absolute dose difference is in units of Gy. The number of patients per treatment-site are
shown in parentheses.

Per-plan 3%/2mm gamma pass rates were calculated on the patient anatomy using both
10% (standard) and 85% (target region) dose thresholds. Isolating delivery error, every pass
rate was greater than 99%. Isolating calculation difference, the 42 per-plan gamma pass rates
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were 87 ± 12% and 55 ± 27% for 10% and 85% thresholds respectively. The distribution of
gamma results are shown in Fig. 15. Given the poor agreement in PTV Dmean dose between CS
and MC in Fig. 14a, these poor gamma passing rates are expected.

Figure 15. Histogram plot of 3%/2mm gamma pass rates (Plan-MC vs. Plan-CS) using both 10% and 85%
dose thresholds.

Clinical per-beam 3%/2mm ArcCHECK gamma passing rates were compared to a
variety of per-beam LF-MC QA metrics as calculated on the patient anatomy. These metrics
included PTV Dmean, PTV D99, PTV D95, and PTV D1 as well as 3%/2mm gamma calculated
using 10% and 85% thresholds. Using a linear fit, R2 correlations were drawn both when
delivery error and calculation differences were isolated. When isolating delivery error (LF-MC
vs. Plan-MC), R2 values were all near zero. AC gamma pass rates had no correlation with
delivery-error-only LF QA metrics as calculated on the patient’s anatomy. Isolating calculation
difference (Plan-MC vs. Plan-CS), R2 values were small, but non-negligible. PTV Dmean
yielded an R2 correlation of 0.24 with respect to AC passing rate. The other PTV metrics had
correlations of 0.12-0.14 while the gamma metrics were 0.05-0.08. AC gamma pass rates were
largely uncorrelated with both gamma-based and DVH-based LF QA metrics on the patient’s
anatomy. It is the goal of radiotherapy to delivery accurate dose on the patient’s anatomy. This
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disconnect between AC QA results on the phantom geometry and LF QA results on the patient
geometry suggest that AC QA is simply not capable of detecting clinically relevant dosimetric
errors as calculated on the patient anatomy.
Difference in TCP (TCPPlan-MC - TCPPlan-CS) was on average -3.1 ± 1.8%. Out of 42
plans, 29/18/13/6/3 plans had drops in TCP greater than 2/3/4/5/6%. A histogram plot of the
per-plan decrease in TCP as measured using LF-MC QA is displayed in Fig. 16. The
significance of this drop in TCP is discussed later, however, suffice it to say for now that these
are fairly significant drops in TCP.

Figure 16. A histogram plot displaying reduction in TCP (Plan-MC vs. Plan-CS).

Gantry discretization difference, illustrated in Fig. 17, was assessed for LF-CS QA.
Subfigure 17a displays the effects of gantry discretization difference (LF-CS(1°) vs. Plan-

72

CS(4°)) on various PTV DVH metrics. Subfigure 17b displays the same values except for
reduced gantry discretization difference (LF-CS(1°) vs. Plan-CS(2°)). Dose variations for LFCS(1°) vs Plan-CS(4°) were 0.45 ± 1.95%, 0.14 ± 0.96%, and 2.63 ± 4.07% for PTV Dmean, D99,
and D1 respectively. Dose variations for LF-CS(1°) vs Plan-CS(2°) were 0.0 ± 1.99%, 0.20 ±
1.16%, and 0.67 ± 1.12%. Utilizing Plan-CS(2°) instead of Plan-CS(4°) resulted in reduced
dose differences. Mean PTV Dmean dose difference decreased from 0.45% to 0.0%. Mean PTV
D1 dose difference decreased from 2.63% to 0.67%. These results show that the dosimetric
difference due to gantry discretization is typically on the order of 0-2%, however PTV D1
differences as large as 4% are possible for more severe cases. Although a 0.5% difference in
PTV Dmean is not hugely significant, this dose difference is large with respect to dose difference
due to delivery error. Thus, it is the recommendation of this study that Plan-CS(4°) be
interpolated to Plan-CS(2°) when carrying out LF-CS QA.

Figure 17. Histogram plots of percent dose difference in key PTV DVH metrics as a result of a) gantry
discretization difference and b) reduced gantry discretization difference.

3.3.3 Dose Discrepancy (MC vs CS)
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In section 3.1, both dose calculation algorithms were shown to be accurate within 3%,
however, when dose is calculated and compared on the patient anatomy in section 3.2,
significant dosimetric differences greater than this 3% were seen. Thus, the cause of this
difference was investigated within the scopes of beam complexity and patient heterogeneity.
3.3.3.1 Beam Complexity
Variation in PTV Dmean, PTV D99, GTV Dmean, and GTV D99 with respect to MU/Rx yielded
R2 correlations of 0.35-0.41. R2 correlation for the external ROI was 0.67. These correlations
suggest a significant portion of LF-MC QA dose discrepancy as calculated on the patient
anatomy is due to beam complexity. GTV D99, the target ROI with the greatest correlation
value, is plotted against MU/Rx in Fig. 18. As displayed in Table 12, variation in GTV D99
was investigated for simple (< 3.5 MU/Rx) plans and complex (> 3.5 MU/Rx) plans. For simple
plans, ΔGTV D99 was -3.89 ± 1.92%. Dosimetric variation was greater for the complicated
plans; ΔGTV D99 was -6.64 ± 1.97%.

Figure 18. Per-plan Percent variation in GTV D99 (MC – CS) is plotted as a function of the beam
complexity MU/Rx.
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Table 12. Dose discrepancy is evaluated for simple (MU / Rx < 3.5) and complicated (MU / Rx > 3.5)
patient cases.
Metric (MC – CS)

27 Simple Cases

15 Complex Cases

ΔGTV D99

-3.9 ± 1.9

-6.6 ± 2.0

ΔPTV D99

-3.7 ± 2.2%

-6.4 ± 2.6%

ΔTCP

-2.7 ± 1.6%

-3.9 ± 1.9

Variation in TCP with respect to MU/Rx yielded an R2 correlation of 0.15. For the 27
simple plans, ΔTCP was -2.57 ± 1.70%. For the 15 complicated plans, ΔTCP was even greater
at -3.94 ± 1.89%. The low correlation between TCP and MU/Rx is to be expected. Above,
GTV D99 was shown to have a 0.42 R2 correlation with MU/Rx. All other DVH metrics had
lower R2 values. It follows that TCP, which is one step further removed from MU/Rx, will thus
have an R2 values lower than 0.4. In addition, we know that ΔTCP is proportional to Δ(dose
difference) multiplied by γ50 in the central non-shoulder part of the dose response curve.
However, the 42 cases studied all have varying values of γ 50. This will result in even further
reduced values of correlation between TCP and MU/Rx.
3.3.3.2 Patient Heterogeneity
Displayed in Fig. 19, per-plan percent difference in PTV Dmean was calculated for both
the heterogeneous patient anatomy, as well as when the anatomy was fully overridden to unit
density. Heterogeneity was evaluated per-site for two treatment sites with greater heterogeneity
- lung and H&N. Five lung and five H&N plans having a range of dose calculation agreement
were selected. For the five H&N patients, MC – CS agreement was actually poorer on the
homogeneous anatomy. Dose agreement decreased by 10 ± 23% when overriding the patient
to water. This indicates heterogeneity effects were largely insignificant for the H&N cases.
For the five lung patients, MC – CS agreement was better for four of them on the homogeneous
anatomy. On average the dose variation was 18 ± 21%. This indicates ~20% of the lung dose
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variation due to calculation differences was due to heterogeneity effects. CS dose variation
with respect to MC was mostly seen at the outer surface of higher density tumor voxels proximal
to low density lung tissue. This over estimation of target dose by CS is likely due to poor
estimations when it comes to loss of lateral scatter equilibrium in low density media. 16

Figure 19. Per-plan percent difference in PTV Dmean due to dose calculation difference is displayed.

3.4. Discussion
LF-MC QA yielded PTV Dmean and PTV D99 dose discrepancies greater than 5% for 14%
and 40% of patients respectively. The clinical impact of this discrepancy is best evaluated
within the scope of TCP as no other metric can as succinctly quantify the effectiveness of a
treatment plan. Decrease in TCP, calculated using GTV, was on average -3.1 ± 1.8%. Out of
42 plans, 29/18/13/6/3 plans had drops in TCP greater than 2/3/4/5/6%. The effect of these
drops in TCP can best be evaluated in terms of recurrence rates. By definition, TCP quantifies
the probability that 0 clonogenic cells survive the radiotherapy treatment. However, it is not
necessary to kill every clonogenic cell. In reality, only enough cells need to be killed that the
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re-development of a symptomatic tumor is prevented for the remaining duration of the patient’s
life. This relapse time, or time at which a symptomatic tumor is expected to return, can be
calculated via Eq. 13, where G(t) is the probability of recurrence at time t, P m is the probability
𝒎
𝑮(𝒕) = ∑∞
𝒎=𝟎 𝑷𝒎 [𝑮𝟏 (𝒕)]

(14)

that m number of clonogenic cells remain after radiotherapy, and G 1(t) is the probability that a
clonogenic cell does not become a symptomatic tumor at time t. 15 For example, given a decrease
in TCP from TCPPlan-CS to TCPLF-MC, a new probability distribution function detailing the
probability of m number of clonogenic cells surviving can be calculated. Subsequently a new,
higher, probability of recurrence at time t can be calculated. Following this train of thought,
allowable decrease in TCP is really a patient-specific problem.
Despite substantial dose disagreement as determined using LF-MC QA on the patient
anatomy, ArcCHECK QA results were consistently passing. LF-MC QA dose discrepancy
stemmed primarily from dose calculation method. Values of PTV Dmean and PTV D99 were 3.4 ± 1.9% and -4.6 ± 2.8% lower for MC than CS for the 42 patient cases. 77/7/1 fields had
pass rates of 95-100%/90-95%/87%. Furthermore, DVH-based LF-QA results were largely
uncorrelated with clinical AC gamma pass rates.

It follows that the coefficients of

determination between the LF-MC QA results and gamma results were quite low. PTV D mean
displayed the greatest correlation with clinical 3%/2mm gamma passing rates with an R2 of
0.24. All other LF QA metrics had R2 values less than 0.14. Discrepancy in LF-MC QA and
AC QA results can be attributed to several factors. Foremost is the mismatch in geometries
utilized. A homogeneous, symmetric cylindrical phantom is not representative of the patient’s
anatomy. The phantom will not be able to account for patient-specific heterogeneities. In
addition, when delivering IMRT planned doses which have been optimized on the patient’s
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anatomy onto a different geometry (e.g. ArcCHECK), the uniform target dose is blurred across
a greater region. Simultaneously, the dose difference (e.g. MC vs. CS) is spread out over a
greater volume, resulting in lower local percent variations in dose. This percent dose variation
is further decreased when utilizing a global dose criteria (e.g. Van Dyke). Lower dose variance
will yield higher gamma pass rates. Lastly, the diode detectors are placed at a fixed depth that
likely does not correspond to the target location. If follows that the diode measurements are
not as applicable as they maybe ought to be.
The failing AC QA result was addressed. The case was a four arc VMAT H&N case.
Of the four arcs, one yielded an ArcCHECK pass rate (Plan-CS vs. AC) of 87.2%. Comparing
Plan-MC to AC, a 3%/2mm gamma pass rate of 92.3%. Upon further investigation it was
determined that this failure resulted from delivery error. By reconstructing LF-CS dose on the
ArcCHECK geometry, an LF-CS vs. AC passing rate of 100% was calculated. Similarly, LFMC vs. AC also yielded a 100% passing rate on the ArcCHECK geometry. Digging into the
log file, this delivery error was determined to result from the non-linear delivery of MU/degree
as well as gantry error up to 1.4 degrees. Importantly, this non-linearity in MU/degree
coincided at the same gantry angle as where the gantry error occurred. When dose is calculated,
MU output is assumed to be linearly delivered between control points, however, this is not
always the case. The ArcCHECK failure pattern which was caused by this delivery error is
circled in Fig. 20. Fig 21 and Fig. 22 display the non-linear MU/degree output and gantry error
respectively. Despite this delivery error and low 3%/2mm gamma passing rate, dosimetric
discrepancy due to delivery error on the patient anatomy was minimal; variations in PTV D mean
and PTV D99 were -0.7 and -2.6% respectively. This demonstrates that delivery errors as
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measured on the ArcCHECK phantom do not necessarily translate into DVH-based errors on
the patient anatomy.

Figure 20. An ArcCHECK failure pattern for Plan-MC vs. AC resulting from gantry error and non-linear
MU/° is shown.

Figure 21. MU/° is plotted as a function of gantry angle.
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Figure 22. Gantry error is plotted as a function of gantry angle.

Dose discrepancy due to delivery error was extremely small for all cases studied. Delivery
error peaked at 0.8% of the fractional prescribed dose and was typically within a few tenths of
a percent. In comparison, despite excellent square-field water tank validation results, dose
discrepancy due to dose calculation method was large. This disagreement was investigated
within the scopes of tissue heterogeneity and beam complexity.

The effect of tissue

heterogeneity was greatest for lung tumors; 20% of dose discrepancy was explainable by
heterogeneity effects. However, heterogeneity did not play a significant role for other treatment
sites. In comparison, 40% of dose discrepancy was explainable by beam complexity over all
treatment cases. Table 12 shows that dose discrepancies were much greater for the complicated
(MU / Rx > 3.5) treatment cases. These results were investigated within the scope of treatment
planning QA – “Given these results, is there some way this dose difference can be mitigated?”.
CS and MC inherently model tissue heterogeneities differently.

CS is not designed to

accurately account for inhomogeneities, thus little can be done to mitigate these calculation
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differences. However, when it comes to beam complexity, action can be taken to reduce beam
complexity. The most obvious method is to increase the minimum leaf pair gap that can utilized
for VMAT treatment. This will result in smaller MU/Rx values, and thus should result in
greater CS dose calculation accuracy. At out clinic a minimum leaf gap spacing of 6mm is used
for VMAT treatment planning. However, several studies have recommended that minimum
leaf gap spacings should be set to ≥2cm to minimize variation in calculated and measured
dose.102-104 Difference in MC and CS IMRT/VMAT dose is largely attributed to this difference.
Monte Carlo beam models may not always be available for every institution, machine,
and/or energy. Thus, LF-CS QA was also evaluated. Specifically, CS gantry discretization
difference was assessed. Assuming LF-MC vs Plan-MC to be the gold standard for estimating
delivery error, dose variations for PTV Dmean, D99, and D1 were a very small 0.11 ± 0.10%, 0.12
± 0.11%, and 0.20 ± 0.18%. However, comparing LF-CS to Plan-CS, dose variation could be
large due to gantry angle discretization. Comparing Plan-CS(4°) to LF-CS(1°), PTV Dmean and
D1 dose variations were 0.5 ± 2.0% and 2.6 ± 4.1%. Linearly interpolating Plan-CS(4°) to PlanCS(2°), dose variation with respect to LF-CS decreased to 0.0 ± 2.0% and 0.7 ± 1.1%
respectively. Using 2 degree control point spacing, LF-CS QA is capable of verifying delivery
error within fairly tight bounds; Plan-CS PTV metrics were generally accurate within 1% of
LF-CS(1°) and almost always accurate within 2%.
MC agreement with measurement was superior to that of CS. In-field and out-of-field, MC
confidence limits were 2.4% and 4.2% respectively. In comparison, CS confidence limits were
6.3% and 6.1%. Across all 10 institutions in TG-119, confidence limits were 4.5% in-field and
4.7% out-of-field.49 However, whereas much of the data acquired in TG-119 is for IMRT cases
and simpler treatment sites, the VMAT cases utilized in this TG-119 study were relatively more
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complicated. This increased complexity is hypothesized to result in the higher CS confidence
limit.

However, given the ±5% dose goal, the 6% CS confidence limits are somewhat

unacceptable. In comparison, the MC confidence limits, especially in-field, were very good.
Three methods are introduced for addressing the aforementioned decreases in dose and
tumor control. First, it may be preferable, once the computational cost of Monte Carlo is
sufficiently low, to simply utilize a TPS that utilizes MC in the plan optimization process.
Second, the planned number of MU could be simply scaled by a scaling factor, SF = CS PTV
D99 / MC PTV D99. Third, the direct machine parameter optimization (DMPO) process could
be constrained. For example, many of the worst cases in this study were highly complicated
H&N or breast cases. An investigation into aperture shape revealed many segments with thin
(< 1cm) snake-like apertures. Increasing the minimum dynamic leaf pair gap in the Pinnacle
TPS should yield simpler beam segments and thus smaller ΔTCP values.
LF-MC QA is intended to fully replace conventional phantom-based QA systems. As such,
new protocols are required to determine whether the results of LF-MC QA on the patient
anatomy should be considered passing or failing. Initially, a |ΔTCP D99| < 4% action tolerance
was investigated. This tolerance was selected given that dose calculation methods are typically
expected to be accurate within 3-4%.19 However, this resulted in a 41% failure rate. Given
clinical workload constraints, the number of failing cases should not be more than 10%.
Investigating various criteria, an action tolerance of |ΔPTV D 99| < 5% and |ΔTCP| < 4% was
decided upon. Using this criteria, 8/42 cases failed. However, of these eight cases six were
complicated fields (MU/Rx > 3.5). Given the dependence of dose discrepancy on beam
complexity, it is the recommendation of this study that physicists/dosimetrists attempt to limit
MU/Rx < 3.5 if using CS or an equivalent algorithm. With a total of 27 simple cases, the
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remaining 2 failures represents a 7% failure rate. For these failures it is the recommendation
that the prescription dose to the patient be multiplied by the aforementioned scaling factor, SF,
and that the plan be re-optimized.
In general, OAR dose discrepancies were less significant than target dose discrepancies.
This was largely due to MC calculation being systematically lower than CS. As negative OAR
discrepancies will result in lower normal tissue complication probability (NTCP) values,
negative discrepancies were not assessed. Variation in OAR dose due to calculation difference
was assessed using 1Gy/3%, 2Gy/3%, and 3Gy/3% passing criteria. Over the 42 plans analyzed
in this study, roughly 1000 dose-volume constraints were QAed. Of these 1000 constraints, 19
failed using a 1Gy/3% criteria. Of these failures, 12 failures were for Cochlea D1%; mean
variation was 3.9 ± 1.8Gy. The remaining failures included brain stem, oral cavity, esophagus,
bladder, penile bulb, brachial plexus, and mandible ROIs receiving 1.04, 1.21, 1.18, 1.05, 1.07,
2.18, and 3.83Gy more dose via MC than CS. Variation in OAR dose due to delivery error was
assessed using a 0.5Gy/1% criteria. Of the 1000 dose-volume constraints, there was one failure;
a cochlea D1 varied by 0.7Gy/5%. Although a couple of these dose discrepancies were
moderately large, the previously analyzed variations in target dose were more significant. Thus,
given workload constraints, none of these variations were considered significant enough to label
LF-MC QA as failing.
Although MC and CS calculation typically matched measurement within 2% and 3%
respectively in a homogeneous media, calculation matched measurement poorly for a subset of
the TG-119 & clinical VMAT cases. This trend is similar to what was shown by Bouchard et
al.98 Out of 1600 IMRT measurements in a phantom, 1300 agreed within 2%. Calculation
disagreement ranged from -12.7% to 11.7% for the other 300 cases. It is important to note these
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measurements were taken using the same size ion chamber as utilized herein. However, for
this size ion chamber, correction factors for dynamic IMRT fields can be greater than 10%. 59
This suggests that any disagreement between calculation and measurement for IMRT/VMAT
fields in this study could very well be due to measurement inaccuracy.
Comparing Plan-MC to Plan-CS, dose discrepancy was assessed as a function of
heterogeneity, beam complexity, and gantry discretization.

PTV D mean dose discrepancy

stemmed ~10% from heterogeneity, ~40% from beam complexity (MU/Rx), ~10% from gantry
discretization, and ~40% from unknown sources. However, it is important to understand that
these values are approximations. First, MU/Rx, although a simple and apt metric for indicating
beam complexity, is simply an approximation of beam complexity. Second, overriding the
patient anatomy to water, although a good experiment for assessing the effect of heterogeneity,
is not simple to quantify. It follows that some additional fraction of the unexplained variance
is likely due to beam complexity and/or heterogeneity.
3.5 Conclusion
Delivery errors, as tracked from linac log files, as well as calculation differences
(ScientificRT’s SciMoCa Monte Carlo vs. Pinnacle’s Convolution-Superposition) were
assessed on patient anatomies. Differences in DVH metrics due to delivery error were typically
on the order of a couple tenths of a percent, indicating delivery errors for the Elekta Infinity
linac equipped with an Agility treatment head were very minimal. Dosimetric difference due
to gantry angle discretization error was moderate. When using LF-CS QA, Plan-CS should be
interpolated to ≤ 2° control point spacing. Whereas phantom-based AC QA was consistently
passing, LF-MC QA was able to catch clinically worrisome dose discrepancies as calculated on
the patient’s anatomy.

Percent differences in PTV Dmean, PTV D99, and TCP as large as 7%,
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10%, and 7% on the patient anatomy. Reductions in TCP as large as 7% were also calculated.
Dose discrepancy was primarily due to beam complexity. For instance, when using an action
tolerance of [|ΔGTV D99| < 5% and |ΔTCP| < 4%] for patient anatomy-based planning QA, 7%
of simple (MU/Rx < 3.5) cases and 53% of complicated (MU/Rx > 3.5) cases failed. Thus, it
is recommended that treatment planning beam complexity be constrained within MU/Rx < 3.5
if dose is calculated using CS of an equivalent algorithm. It is concluded that, given proper
machine QA and Monte Carlo commissioning, anatomical LF-MC QA is a fully automatable
technique with the potential to fully replace phantom-based QA techniques.
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CHAPTER 4 LF QA SOFTWARE
LF QA software was developed alongside the aforementioned research.

Fig. 23

illustrates the general architecture of LF QA. There is a central LF QA server that is in charge
of LF QA. The server receives log files from a linac or linacs. It queries Mosaiq to match a
log file to the correct patient. It is connected to a linux server dedicated for the management
and calculation of Monte Carlo doses. Lastly, it’s setup so that one or multiple physicists’
computers can easily initiate LF QA and analyze the results in Pinnacle. The LF QA software
consists of three main components: (1) a system for automatically archiving log files in a
manner where log files can easily be acquired when required; (2) LF-CS QA; and (3) LF-MC
QA. Fig. 23 illustrates the key systems of LF QA.

Figure 23. Log File QA Workflow. A central log file server acquires the log files from the linacs, matches
the log files to a patient’s plan using Mosaiq, calculates dose using SciMoCa, and pushes the resultant dose
to Pinnacle for evaluation.
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4.1 Log File Acquisition & Storage
First, acquisition of log files is discussed. Ideally, log files should be pushed to a log
file server immediately upon the delivery of the field. This would allow the log file to be
processed and log file dose to be calculated as soon as possible. Unfortunately, this method is
not provided by Elekta. Thus, Elekta log files were acquired using the following two methods.
First, log files can be manually exported by the physicist by putting the linac into service mode.
This process takes roughly 10 minutes. The exported file is a zip file which contains per-field
log files in binary .trf format. This export includes log files from the last 8 days. The benefit
of this method is log files can be acquired and pushed to the log file server for processing in 10
minutes. The disadvantage of this method is that it requires the physicist to manually export
log files. The second method used to acquire log files is routine and automatic, but not quick.
The linac hard disk (specifically, the D: drive) is backed up to a set location on a weekly basis.
Both manually exported and weekly automatically exported log files are sent to the same
location. The log file server is setup to monitor this location and process files when they are
acquired. For the weekly linac snap shots, the disk image is programmatically mounted as a
virtual share drive. The log files (.trf) are then acquired from the share drive and the disk image
is unmounted.
Binary trf files are then converted into ASCII .csv files. Unfortunately, the log file
contains limited information as it pertains to patient and/or beam identification. However, we
do know when the beam was delivered and on what machine. By querying Mosaiq this is
enough information to determine what patient this log file is for, as well as which treatment
plan and which treatment field, etc. Log files, both trf and csv, are then stored in a directory of
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the following format: Database / MachineName / PatientID / TreatmentName / DeliveryDate /
FieldID. A PostgreSQL database is setup to store information about all relevant log files.
4.2. LF-CS QA
LF-CS QA is carried out on the patient’s anatomy using the methods described in
previous chapters. The csv log file is converted into a Pinnacle script that in turn creates a plan
in Pinnacle. From here, dose is calculated and analyzed in Pinnacle. This is a semi-automatic
process. From the LF QA software, the physicist selects which fields they want to reconstruct
log file dose for. This spawns a program which converts the log files of interest into two
pinnacle scripts which are sent to the Pinnacle server. The physicist then opens Pinnacle, runs
the first script (initialize beams and control points), runs the second script (sets beams to match
the log file samples), and calculates dose.

Pinnacle scripting is not particularly quick.

Converting 358 log file samples into 358 control points for a 358° VMAT arc (1° control point
spacing) can take close to an hour. Dosimetric analysis of the reconstructed log file(s) in
Pinnacle is left to the discretion of the physicist.
4.3. LF-MC QA
LF-MC QA is initiated in the same way as LF-CS QA. The physicist selects which fields
they want to reconstruct LF-MC doses for and clicks ‘Run LF-MC QA’ in the GUI. This
spawns a program on the LF QA server. This program first queries a PostgreSQL database that
contains path locations for each beam / trial in Pinnacle. The query returns a full path location
on the Pinnacle server. From this location, a variety of Pinnacle files are acquired and converted
into DICOM format. Monte Carlo calculation is carried out using these DICOM files (CTs,
RTSTRUCT, RTPLAN). This process then converts the MC doses (Plan-MC, LF-MC) into
binary Pinnacle format and creates a Pinnacle script to load the doses into Pinnacle. In total,
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this process typically takes ~10 minutes. SciMoCa dose calculation usually takes ~2 minutes
per VMAT arc using a 3mm dose grid and 1% statistical uncertainty. Fig. 24 shows the client
GUI that physicists can use to automatically carry out Plan-MC and LF-MC doses as part of
LF-MC QA. Fig. 25 shows a sub-GUI that is utilized to export doses to Pinnacle for further
evaluation.

Figure 24. LF QA GUI for calculating Plan-MC and LF-MC doses. Doses can also be exported to a separate
tool which is utilized for LF-CS QA.
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Figure 25. GUI for selecting doses to export to Pinnacle for evaluation.
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CHAPTER 5 CONCLUSION
Accurately reconstructing dose on each patient’s unique anatomy, LF-MC QA has shown
great potential for patient-specific QA. Using Monte Carlo, dose calculation accuracy was ~1.2%
(1σ) and generally within 2% for complex VMAT fields delivered on a homogeneous solid
water stack. In addition, SciMoCa was shown to be able to accurately calculate dose in a
heterogeneous cork phantom within 2%. In comparison, this study has shown conventional
phantom-based QA to be generally lacking. In Chapter 2, diode sensitivity dependence on dose
rate, beam complexity, and energy was investigated. Diode sensitivity varied up to 1.5% infield with dose rate and up to 5% out-of-field with energy. Phantom-dependent uncertainties
were on average 0.8 ± 1.2%. In Chapter 3, ArcCHECK gamma passing rates were consistently
passing even though DVH differences ≥5% were calculated using LF-MC QA on the patient
anatomy. In follows that AC pass rates were uncorrelated with both DVH-based and gammabased LF-MC QA metrics as calculated on the patient anatomy (R2 < 0.24). Finally, even when
the ArcCHECK phantom registered a poor passing rate due to the combined effects of gantry
error and non-linear MU, these delivery errors negligibly impacted anatomical DVHs. It is
therefore the conclusion of this study that ArcCHECK, and perhaps phantom-based QA systems
in general, is not an ideal method of patient-specific treatment plan QA. In comparison, LFMC QA was able to not only accurately determine the delivered dose distribution on the patient,
but also accurately determine the cause of potential dose differences. In addition, this QA
technique also provide a possibility for online or real-time planning modification/treatment.
Despite the significant advantages of LF-MC QA over AC QA, there exist strict
requirements that LF-MC QA must abide by. The two primary requirements of LF QA are that
it relies on reliable machine QA and an accurate dose calculation method. The 6MV SciMoCa
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Agility beam model utilized as part of this study was shown to accurately calculate dose within
2-3% for both heterogeneous anatomy and complicated MLC segments.

However, it is

essential that each institution thoroughly vet each of their MC beam models. LF-MC QA also
relies on proper machine QA. Variations in output and beam tuning are not monitored via log
files and thus must be sufficiently monitored via machine QA. In addition, MLC calibration
must be maintained. However, these disadvantages are addressable – strictly maintain machine
QA and/or expand upon current machine QA protocols. In conclusion, although LF-MC QA is
not flawless, it is a superior form of patient-specific QA to AC QA.
LF QA on the phantom geometry yielded equivalent results as AC QA. It follows that LF
QA on the phantom geometry can fully replace AC QA. Furthermore, LF QA on the phantom
geometry allows for root cause of analysis of any potential delivery errors. However, given
concerns with phantom-based QA in general, neither ArcCHECK QA nor LF QA as calculated
on the phantom geometry are recommended forms of QA.
A benefit of this study and the benefit of LF-MC QA is that it is immediately clinically
impactful. This study was immediately clinically impactful at our institution as well. This
study showed us that machine delivery error is very small and generally clinically negligible
for our Elekta Agility machine. Instead dose calculation was shown to be extremely
important. Investigating dose calculation further, it was found that complexity was the
primary concern of dose calculation accuracy at our institution. As a result, we changed our
minimum leaf gap in our treatment planning system to be 1.5cm instead of 0.6cm. We also
notified our dosimetrists that plans should ideally be within 3.5 MU / Rx. The greatest
clinical takeaway from this study is that ArcCHECK QA and perhaps phantom-based QA is
largely irrelevant. ArcCHECK QA was incapable of catching clinically relevant dosimetric
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errors as determined via LF-MC QA on the patient anatomy. Thus, despite being the standard
of care for decades, ArcCHECK absolutely should not be the primary form of patient-specific
QA in clinics. In comparison, Elekta LF-MC QA has no real weaknesses. LF QA relies on
accurate dose calculation, but Monte Carlo has been shown to be very accurate given proper
beam modeling. LF QA also relies on accurate machine QA, but it is not the responsibility of
patient-specific QA to reconfirm accurate machine QA.
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Purpose: Monte Carlo-based log file quality assurance (LF-MC QA) is investigated as
an alternative method to phantom-based patient-specific quality assurance in radiotherapy (e.g.
ArcCHECK QA (AC QA)).
Methods: First, the shortcomings of AC QA were investigated.

The sensitivity

dependence of ArcCHECK diodes on dose rate (in-field) and energy (primarily out-of-field)
was quantified. LF-MC QA was then analyzed on the phantom geometry. Planned (‘Plan’)
and LF-reconstructed CS and MC doses were compared with each other and AC measurement
via statistical (mean ± StdDev(σ)) and gamma analyses to isolate dosimetric uncertainties and
quantify the relative accuracies of AC QA and LF-MC QA. LF-MC QA was then analyzed on
the patient geometry. Calculation algorithm dependent (Plan-MC vs Plan-CS) and delivery
error (LF-MC vs Plan-MC) dependent dosimetric discrepancies were isolated.

Dose

discrepancies were evaluated using PTV Dmean, D99, and D1 as well as tumor control probability
(TCP). Dose discrepancy due to calculation algorithm was further assessed as a function of
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heterogeneity and beam modulation complexity (MU/Rx). LF QA results were compared to
clinical AC QA results. Various LF-MC QA pass/fail protocols were assessed.
Results: Calculation and ArcCHECK measurement differed up to 1.5% in-field due to
variations in dose rate and up to 5% out-of-field due to energy effects. On the ArcCHECK
geometry, phantom-dependent, calculation algorithm-dependent (MC vs. CS), and delivery
error-dependent dose uncertainties were 0.8±1.2%, 0.2±1.1%, and 0.1±0.9% respectively. On
the patient anatomy, percent differences in [PTV Dmean, D99, D1] were [-0.1±0.1%, 0.0±0.2%, 0.2±0.2%] for machine delivery error, [-3.4±1.9%, -4.6±2.8%, -1.2±2.8%] for dose calculation
difference, and [0.5±2.0%, 0.2±1.2%, 2.6±4.1%] due to limited VMAT beam sampling. Drop
in TCP due to calculation difference (MC-CS) was -3.1±1.8% [min -5.7%]. 41% of PTV D99
dose calculation difference was due to beam complexity. Heterogeneity effects were negligible
for H&N.

For lung, 18% of dose calculation difference on PTV Dmean was due to

heterogeneity
Conclusions: ArcCHECK QA was consistently incapable of catching clinically relevant
dose discrepancies as calculated on the patient anatomy using LF-MC QA.
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